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PREFACE 
My journey to writing this dissertation began as child who watched her mother 
prick her finger every single day to check her blood sugar levels. As I grew to be a 
graduate student, I felt it was my purpose to research type 2 diabetes and contribute to 
improved therapies not only for my mother and other family members with the disease, 
but also for all people who continue to suffer from type 2 diabetes.  
My primitive research goals involved understanding how inflammation 
contributed to diabetes. With great mentoring and more focus, I have spent the last 5 
years researching the role of palmitic acid, a common saturated fatty acid derived from 
the diet, in the progression of inflammatory mechanisms in type 2 diabetes. Based on 
current knowledge in the fields of lipid biology, immunology, and type 2 diabetes the 
objective of this dissertation is to present the data I have been able to gather in support of 
the hypotheses underlying construction of the following diagram (Figure i). After 
presentation of the data in this dissertation, Figure i will be presented a second time as a 
working model for describing the role of palmitic acid in the stimulation of type 2 
diabetes inflammation.  
 
 
xviii 
 
Figure i. Outline of Hypotheses tested in this dissertation. Hypotheses: (1) The 
differentiation of dendritic cells from monocytes is regulated by epigenetic changes, (2) 
palmtic acid activates dendritic cells, and (3) anti-palmitic acid antibodies are present in 
human serum. 
 
This dissertation should be of interest to endocrinologists, immunologist, and lipid 
scientist, as well as dietitians and public health professionals who desire a more complete 
understanding of the etiology of type 2 diabetes. For me, completion of this dissertation 
has been a gratifying journey. Please enjoy the experience of my journey as you read.  
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ABSTRACT OF THE DISSERTATION 
Palmitic Acid Activation of Dendritic Cells: Implications for Type 2 Diabetes 
by 
Dequina Nicholas 
Doctor of Philosophy, Graduate Program in Biochemistry 
Loma Linda University, September 2015 
Drs. William Langridge and Marino De Leon, Co-Chairpersons 
 
Infiltration of immune cells into visceral adipose tissue is observed in type 2 
diabetes development. Monocytes are recruited to obese visceral adipose tissue in large 
numbers and retain the ability to differentiate into dendritic cells, important antigen 
presenting cells in the immune system. Differentiation of monocytes into dendritic cells 
likely accounts for the increased number of dendritic cells observed in the adipose tissue 
of type 2 diabetic patients. We have demonstrated this differentiation process is regulated 
in part by a major reduction of linker histone proteins. In adipose tissue, dendritic cells 
are exposed to high levels of saturated fatty acids. Increased saturated fatty acid levels 
derived from high fat diets are strongly associated with chronic adipose tissue 
inflammation. Palmitic acid, the most abundant of saturated fatty acids, is pro-
inflammatory and has been linked to insulin resistance. However, the mechanisms 
underlying palmitic acid induction of inflammation remain unknown. We have confirmed 
palmitic acid binding to Toll-like receptor 4 (TLR4) on human dendritic cells. In 
response to palmitic acid activation of TLR4, dendritic cells were shown to secrete pro-
inflammatory cytokines that may lead to insulin resistance. In addition, we identified 
anti-palmitic acid IgG antibodies in the serum of patients with unmanaged type 2 
diabetes. In conclusion, diet-derived saturated fatty acids may act as mediators of chronic 
xx 
inflammation associated with type 2 diabetes. Together, the experimental data presented 
support the hypothesis that palmitic acid is an inducer of dendritic cell induced 
inflammation and is an important target for type 2 diabetes therapy. 
1 
CHAPTER ONE 
INTRODUCTION: FATTY ACIDS, INFLAMMATION, AND TYPE 2 DIABETES 
Abstract  
Approximately 285 million people worldwide have type 2 diabetes, and it is 
projected that this number will more than double by the year 2030. Thus, it is imperative 
to advance our understanding of diabetes pathogenesis. Regulation of diet, obesity, and 
inflammation is thought to play a significant role in improving insulin sensitivity and 
reducing the risk of diabetes onset. Visceral adipose tissue is a major site of inflammation 
in type 2 diabetes, and dyslipidemia is a major factor in the recruitment of activated 
immune cells including macrophages, dendritic cells, T cells, NK cells, and B cells to 
visceral adipose tissue. The Immune cells in adipose tissue are a major source of pro-
inflammatory cytokine production thought to stimulate insulin resistance. In this review 
of the literature, the role of increased dietary free saturated fatty acids and cellular and 
molecular mediators linked to insulin resistance in the initiation of obesity-induced 
inflammation are identified.  In addition, novel concepts in diet-induced inflammation 
and type 2 diabetes are discussed. 
 
Introduction 
Diabetes mellitus is a group of metabolic disorders characterized by high blood 
glucose levels extending over a long period of time. Historically, this group of metabolic 
diseases was first described in an Egyptian manuscript called the Ebers papyrus, dated to 
1550 BCE (Bryan 2010). Egyptian historians noted that this disease was characterized by 
polyuria (frequent urination). In addition, ants were attracted to the urine of people with 
2 
this disease because it was sweet (Bryan 2010). In the first century AD, the Greek 
physician Arateus described “siphon” (diabetes) as “the melting down of flesh and limbs” 
into urine (Engelhardt 1989). People who were suspected to have diabetes were 
diagnosed by “water tasters” who tasted the urine to see if it was sweet (Engelhardt 
1989). By the 17-1800s the term “mellitus” or “from honey” was added to diabetes to 
differentiate it from diabetes insipidus (frequent urination due to dysregulation of 
antidiuretic hormone). In the 1900s, Frederick Banting and Charles Best discovered that a 
deficiency of insulin was responsible for the development of diabetes mellitus (Macleod 
and Banting 1923). Insulin and glucagon were found to be two major hormones 
responsible for regulating blood glucose levels (Cavallero, Malandra et al. 1954). 
Glucose induces the release of insulin, which activates insulin receptors and ultimately 
results in the insertion of glucose transporters into the cell membrane. These glucose 
transporters allow cells to use or store blood glucose, thereby removing excess glucose 
from the blood stream. Without effective insulin, blood glucose levels become 
chronically high and act as an osmotic diuretic. The diuretic property of high blood 
glucose levels causes the trademark symptom of frequent urination noted above. 
Diabetes mellitus can be sub-classified into three major categories: type 1, type 2, 
and gestational diabetes. Type 1 diabetes is a well characterized autoimmune disorder 
which results in targeted destruction of pancreatic islet β-cells, the cells which secrete 
insulin. Type 2 diabetes is representative of 90-95% of all diabetes cases worldwide and 
is a complex metabolic disease generally resulting from insulin resistance. Insulin 
resistance is a state in which the body can produce insulin, but cells cannot utilize it 
effectively. Gestational diabetes occurs in 3-8% of pregnant women and may be caused 
3 
by hormones related to pregnancy or a shortage of insulin (Thomas and Philipson 2015). 
This literature review will be focused on type 2 diabetes and obesity-induced 
inflammatory immune mechanisms implicated in insulin resistance. 
Worldwide, approximately 285 million people have been diagnosed with type 2 
diabetes (Franks, Hanson et al. 2010, Hu 2011). In the U.S., healthcare costs are reported 
to be over 245 billion dollars annually (American Diabetes 2013). The growing incidence 
of type 2 diabetes is tied to a variety of risk factors. Genetic factors such as increased 
appetite and propensity to store abdominal fat may increase the risk of type 2 diabetes. 
However, modifiable factors such as a high energy or high fat diet, and reduced physical 
activity are believed to be the greatest contributors to disease development (Wheeler, 
Montgomery et al. 2012). These environmental factors appear to increase inflammation, a 
third major risk factor for development of type 2 diabetes. Chronic, low-grade tissue 
inflammation, especially in visceral adipose tissue is linked to obesity and development 
of type 2 diabetes (Olefsky and Glass 2010, Winer and Winer 2012). The remainder of 
this chapter will describe how high fat diets affect visceral fat inflammation, and its 
contribution to type 2 diabetes pathogenesis. 
 
Diet, Adipose Tissue, and Type 2 Diabetes 
Adipose Tissue in the Obese State 
For decades, the association between poor diet and obesity in the development of 
type 2 diabetes has been extensively studied. Chronic-low grade inflammation is the 
factor that appears to link all three. Adipose tissue, now recognized as a major endocrine 
organ rather than simply an inert tissue for cushion and warmth, has been identified as the 
4 
major site for obesity-induced inflammation. The main function of adipocytes is to store 
energy in the form of lipids. Their secondary function as an endocrine organ involves the 
secretion of hormones such as leptin, estrogen, resistin and pro-inflammatory cytokines 
such as TNF-α. Recently, adipocytes have been shown to have direct immune function. 
They express CD40 and MHCII, which are involved in the activation of T cells in type 2 
diabetes (Poggi, Jager et al. 2009, Deng, Lyon et al. 2013). Adipocytes can also secrete 
pro-inflammatory cytokines such as TNF-α and IL-1β, contributors to insulin resistance 
(Hotamisligil, Shargill et al. 1993, Hosogai, Fukuhara et al. 2007, Osborn, Gram et al. 
2008). During the lean state, adipocytes synthesize IL-4 and IL-13, cytokines which have 
the ability to induce macrophage differentiation into the anti-inflammatory M2 phenotype 
(Figure 1) (Kang, Reilly et al. 2008). Alternatively, increased visceral adipose tissue 
results in chronic inflammation. In obese individuals, the secretion of pro-inflammatory 
substances such as non-esterified fatty acids (FAs) and cytokines is dramatically 
increased (Karpe, Dickmann et al. 2011).  In the insulin resistant state, adipocytes 
undergo high levels of lipolysis and release free fatty acids (Figure 1). In addition, when 
stimulated by TNF-α (i.e. during obesity-induced inflammation), adipocytes produce and 
secrete the chemokine CCL5, a chemoattractant molecule which can recruit T cells to fat 
tissue (Wu, Ghosh et al. 2007).  
 
Dietary Fatty Acids and Type 2 Diabetes 
As previously mentioned, a large risk factor for type 2 diabetes is a diet high in 
fat. In particular, diets high in saturated fats provide a source of long chain saturated FAs. 
Increased levels of these dietary saturated FAs like palmitic and stearic acids have been 
5 
associated with the onset of inflammation and type 2 diabetes (Storlien, Jenkins et al. 
1991, Kolb and Mandrup-Poulsen 2010, Oliver, McGillicuddy et al. 2010). Palmitic acid 
(PA) is a highly abundant FA and is found primarily in palm oils, meats, and dairy 
products. Because this FA is abundant in the Western diet, dietary FA composition 
contributes significantly to the relative bio-availability and storage of PAs in body tissues 
(Riserus, Willett et al. 2009). The conveience of processed foods coupled with high 
caloric intake may result in obesity which subsequently leads to elevated serum and 
tissue FAs that may be responsible for the onset of insulin resistance (Riserus, Willett et 
al. 2009).  
Increased levels of non-esterified FAs in serum are linked to metabolic 
dysfunction, obesity, and an increased risk for development of type 2 diabetes (Paolisso, 
Tataranni et al. 1995, Charles, Eschwege et al. 1997, Pankow, Duncan et al. 2004, Salgin, 
Ong et al. 2012). Across several studies, non-esterified FAs have been shown to induce 
insulin resistance in liver and skeletal muscle (Boden, Chen et al. 1995, Boden, Cheung 
et al. 2002, Belfort, Mandarino et al. 2005). Too much serum non-esterified FAs are also 
known to induce inflammation responsible for generating systemic insulin resistance 
(Tripathy, Mohanty et al. 2003, Liang, Tantiwong et al. 2013). The mechanism by which 
this pathology may occur is discussed in the following sections.  
 
Saturated Fatty Acid Stimulation of Immune Cells 
Although overall increased free FA levels negatively affect metabolic 
homeostasis, not all non-esterified FAs are created equal. Non-esterified saturated fatty 
acids derived from triglycerides in the diet or from lipolysis from adipose tissue are 
6 
generally considered pro-inflammatory. The most prominent mechanism emerging to 
explain how saturated FAs could impact immunity is focused on activation of the 
pathogen recognition receptor (PRR) Toll-like receptor 4 (TLR4) (Shi, Kokoeva et al. 
2006). Several studies have shown TLR4 to be a link between innate immunity and fatty 
acid-induced insulin resistance (Shi, Kokoeva et al. 2006). Saturated FAs have been 
shown to activate macrophages through TLR4 (Lee, Sohn et al. 2001, Nguyen, 
Favelyukis et al. 2007, Suganami, Yuan et al. 2009). This observation is important 
because TLR4 signaling promotes the maturation of M1 macrophages, a macrophage 
phenotype responsible for secretion of TNF-α, IL-1, IL-6, IL-12, iNOS, monocyte 
chemoattractant protein 1 (MCP-1), and RANTES in inflamed adipose tissue during type 
2 diabetes (Winer and Winer 2012). Saturated FAs have also been shown to activate 
adipocytes and microglia through TLR signaling (Song, Kim et al. 2006, Suganami, 
Tanimoto-Koyama et al. 2007, Wang, Liu et al. 2012). Further, our laboratory has shown 
that PA activates dendritic cells via TLR4 and induces secretion of IL-1β (Chapter 3). In 
further support of this concept, mice with a mutation in or deficient in TLR4 are 
protected from the inflammatory effects of a high-fat diet rich in PA (Suganami, Mieda et 
al. 2007, Davis, Gabler et al. 2008). Lastly, TLR4 in hematopoietic cells is critical for 
development of insulin resistance in adipose tissue (Shi, Kokoeva et al. 2006, Saberi, 
Woods et al. 2009). Although FA interference with TLR4 signaling has been clearly 
demonstrated, the mechanism of how saturated FAs interact with components of the 
TLR4 pathway have only recently been clarified (Chapter 3). 
 
 
7 
Visceral Fat Inflammation in Type 2 Diabetes 
Visceral adipose tissue (VAT) has proven to be a key site for inflammation 
associated with type 2 diabetes (Winer and Winer 2012). There are several views 
regarding how adipose tissue inflammation begins. However, it is generally believed that 
a high fat diet and a subsequent increase in visceral adipose tissue are the underlying 
culprits for attraction of immune cells. Obesity results in apoptotic centers of 
hypertrophic adipocytes (Hosogai, Fukuhara et al. 2007, Rausch, Weisberg et al. 2008), 
leptin secretion, unfolded protein responses activated by ER stress (Hummasti and 
Hotamisligil 2010), secretion of MCP-1 from hypoxia activated macrophages and 
lipolysis that releases free FAs which ultimately lead to immune cell infiltration, 
inflammation, and insulin resistance (Halberg, Khan et al. 2009). Infiltration of visceral 
adipose tissue by immune cells results in low-grade chronic inflammation and secretion 
of pro-inflammatory cytokines which can induce insulin resistance both locally and 
systemically (Figure 1). Although the order of immune cell infiltration is disputed, it is 
becoming well understood that a variety of immune cells are involved in visceral fat 
inflammation (Winer and Winer 2012).  In the following section, we will describe the 
major subsets of immune cells implicated in type 2 diabetes as well as deal with the 
emerging roles of lesser studied immune cell types. 
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Figure 1. Overview of Obesity-induced Inflammation. In the lean state, resident 
macrophages are maintained in the M2 phenotype. A combination of IL-10 from Treg and 
Breg cells, IL-4 from eosinophils and adipocytes, and IL-13 from adipocytes polarize 
macrophages to M2, which also secrete IL-10. In the obese state, adipocytes become 
hypertrophic, form necrotic centers due to hypoxia, and undergo increased lipolysis. These 
conditions polarize macrophages to the M1 phenotype which results in the production of 
pro-inflammatory cytokines and chemoattractant molecules that recruit immune cells to 
the adipose tissue. Likely, increased saturated fatty acids from lipolysis activate 
macrophages and dendritic cells through TLR signaling. Activated M1 macrophages 
secrete cytokines that favor the maintenance of Th1, Th17, and CD8+ T cells. Dendritic 
cells secrete IL-1β which contributes to insulin resistance and directs differentiation of 
naïve T cells into pro-inflammatory subsets. Th1, Th17, and CD8+ T cells secrete classic 
pro-inflammatory cytokines which also polarize macrophages to the M1 phenotype. In 
addition, T helper cells provide stimulation to B cells which result in maximal antibody 
responses. B cells can act as antigen presenting cells and activate pro-inflammatory T cell 
subsets. After T cell help, B cells can differentiate into antibody secreting plasma cells. 
Antibodies from these B cells have the ability to polarize macrophages to the M1 
phenotype and activate macrophages by binding Fc receptors. 
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Monocytes / Macrophages 
Macrophages are presently the most studied immune cells in VAT inflammation. 
Macrophages are antigen presenting cells (APCs) deemed responsible for secreting the 
majority of cytokines during chronic inflammation. During the lean state, M2 
(alternatively activated or anti-inflammatory) macrophages are present in VAT (Winer 
and Winer 2012). It is generally accepted that M2 macrophages survey the tissue, aid in 
remodeling, and help maintain VAT insulin sensitivity. M2 polarization is induced by IL-
4, IL-10, and IL-13 (Lumeng, Bodzin et al. 2007). M2 macrophages secrete IL-10 and 
IL-1 receptor antagonist which are anti-inflammatory and protect against insulin 
resistance (Lumeng, Bodzin et al. 2007).  
Resident macrophages recognize dead adipocytes and can be activated by FAs 
through TLR2 and TLR4 (Cinti, Mitchell et al. 2005). TLR4 induces M1 (classical 
activation) polarization of macrophages. These M1 macrophages differentiate from 
monocytes recruited to VAT during obesity-induced inflammation (Kraakman, Murphy 
et al. 2014). The infiltration of M1 macrophages disrupts the balance of M1/M2 (pro-
/anti-inflammatory) macrophages which results in inflammation. The secretion of TNF-α, 
IL-1β, IL-6, IL-12, resistin, MCP-1 and RANTES by M1 macrophages recruit more 
monocytes and inhibit insulin signaling often through serine phosphorylation (Mantovani, 
Sozzani et al. 2002, Olefsky and Glass 2010). This infiltration of macrophages to the 
VAT plays a key role in obesity-induced inflammation. Inhibiting the infiltration of 
CD11b myeloid cells, namely macrophages, prevents the adverse effects of a high fight 
diet in mice (Wueest, Rapold et al. 2010). In further support, ablating M1 macrophages 
by targeting diphtheria-sensitive CD11c+ cells with diphtheria toxin improved glucose 
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tolerance in diet-induce obese (DIO) mice (Patsouris, Li et al. 2008). Overall, the general 
role of macrophages in VAT inflammation is well defined (Kraakman, Murphy et al. 
2014). However, the initial insult that induces the recruitment of monocytes to VAT is 
still under investigation.  
 
Dendritic Cells 
Dendritic cells (DCs) are professional antigen presenting cells which play a 
dominant role in linking the innate immune response to the adaptive immune response by 
presenting antigen on MHCII molecules to naïve T cells. The role of DCs in obesity-
induced inflammation remains relatively unknown (Lee and Lee 2014). However, studies 
have shown a potential role for both the adaptive immune response and for DCs in 
obesity-induced inflammation (Winer and Winer 2012). A study aimed at examining the 
effect of depleting CD11c+ adipose tissue macrophages in obese diabetic mice indicated 
DCs may play a key role in obesity-induced insulin resistance (Patsouris, Li et al. 2008). 
The authors of this study found that depletion of CD11c+ cells in mice improved obesity-
induced insulin resistance and reduced pro-inflammatory cytokines in the adipose tissue. 
Although these results were attributed to the adipose tissue macrophages, ablation of cells 
positive for CD11c, a classical dendritic cell marker, also depleted circulating DCs, 
which outnumber adipose macrophages (Hashimoto, Miller et al. 2011). Therefore, this 
study also indicates that circulating CD11c+ DCs may contribute to obesity-induced-
inflammation. In support of this conclusion, two laboratories have shown that the 
numbers of DCs in VAT in mice increase during obesity (Bertola, Ciucci et al. 2012, 
Stefanovic-Racic, Yang et al. 2012). Not only that, CD103 DCs, a subset known to be 
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important in the differentiation of Treg cells, is decreased in VAT of obese mice 
(Jaensson, Uronen-Hansson et al. 2008). Interestingly, Bertola et al, showed that DCs 
isolated from VAT of obese mice induced naïve T cells to differentiate in vitro into Th17 
cells, a T cell subset which antagonizes Treg function (Bertola, Ciucci et al. 2012). 
However, changes in Th17 populations in VAT in vivo have not yet been identified. In 
addition to macrophages and B cells, resident DCs recognize dying adipocytes. 
Mechanistic studies from our laboratory and others have indicated how the innate 
functions of DCs may play a role in obesity-induced inflammation. Due to obesity-
induced hypoxia and increased lipolysis in adipose tissue, DCs are activated by apoptotic 
debris and free fatty acids via Toll-like receptors (TLRs) (Cinti, Mitchell et al. 2005) 
(Chapter 3). The activation of DCs through TLRs induces secretion of pro-inflammatory 
cytokines linked to adipose inflammation and insulin resistance. Although there is 
sufficient evidence for the innate function of DCs in obesity-induced inflammation, 
increased research efforts are needed to understand how the adaptive function of DCs 
might influence B and T cells during this chronic inflammatory response.  
 
T Cells 
T cells were identified in VAT almost 15 years ago (Bornstein, Abu-Asab et al. 
2000). T cells regulate macrophage polarization and are thought to regulate inflammation 
during insulin sensitive/resistant states (Winer and Winer 2012). In addition, depletion of 
CD3+ T cells reduced VAT inflammation, glucose intolerance, and insulin resistance in 
diet-induced obese (DIO) mice (Nishimura, Manabe et al. 2009). Believed to infiltrate 
VAT after B cells, T cells and their role in type 2 diabetes inflammation has now been 
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extensively studied (Lee and Lee 2014). Like B cells, T cells are divided into various 
subsets depending on their phenotype and function. T regulatory cells (Tregs) are an anti-
inflammatory subset of T cells which help mediate VAT homeostasis during the lean 
state in mice. Tregs can reduce VAT inflammation and insulin resistance, secrete IL-10 
to polarize macrophages to the anti-inflammatory M2 phenotype, and block TNF-α 
induced pro-inflammatory cytokines such as IL-6 (Lumeng, Bodzin et al. 2007, Winer 
and Winer 2012). Additionally, the percentage of Tregs in VAT directly correlate with 
insulin sensitivity (Feuerer, Herrero et al. 2009). Normally, Tregs comprise 30-50% of T 
cells in VAT and hyper-express IL-10 (Feuerer, Herrero et al. 2009). On the other hand, 
the proportion of Treg cells in VAT decrease during the obese state (Feuerer, Herrero et 
al. 2009, Nishimura, Manabe et al. 2009, Winer, Chan et al. 2009), likely due to the 
increase in recruited pro-inflammatory cells. This same decrease has also been found in 
humans (Zeyda, Huber et al. 2011). 
The pro-inflammatory T cell subsets most implicated in type 2 diabetes 
inflammation are Th1 cells and CD8+ T cells. In general, DIO mice have three times 
more VAT T cells than mice fed a standard diet, indicating increased T cell recruitment 
(Wu, Ghosh et al. 2007). These T cells are found co-localized with clusters of 
macrophages and dying (apoptotic/necrotic) adipocytes called crown like structures 
(CLS) (Olefsky and Glass 2010) (Rausch, Weisberg et al. 2008).The importance of T 
cells in obesity stimulated insulin resistance is highlighted by the fact that the inhibition 
of T cell migration to VAT prevents insulin resistance in DIO mice (Kendall and Hupfeld 
2008). Both the percentage and total number of IFN-γ producing Th1 cells are increased 
in VAT of mice fed a high fat diet (Rocha, Folco et al. 2008, Winer, Chan et al. 2009, 
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Strissel, DeFuria et al. 2010) . This scenario has also been found to occur in humans 
(O'Rourke, Metcalf et al. 2009, Winer, Chan et al. 2009). IFN-γ aids in the polarization of 
macrophages to the M1 phenotype. Th1 cells also secrete IL-12. Th1 deficient IL-12p35 
null mice on a high fat diet have improved insulin sensitivity (Winer, Chan et al. 2009). 
Th1 cells are not the only T cell subset implicated in obesity-induced inflammation. 
CD8+ T cells are found to increase in VAT of DIO mice after 2 weeks (Nishimura, 
Manabe et al. 2009). Most are activated and they co-localize with CLS (Nishimura, 
Manabe et al. 2009). CD8+ T cells help to recruit M1 macrophages as indicated by the 
reduction of M1 macrophages, IL-1, IL-6, TNF-α, MIP-α, and RANTES in VAT when 
CD8+ T cells were abolished (Nishimura, Manabe et al. 2009). Lastly, CD8+ T cells may 
also function in supporting monocyte differentiation (Nishimura, Manabe et al. 2009). 
 
B Cells 
B cells have recently been shown to play a role in type 2 diabetes. They consist of 
two major subsets, B-1 and more commonly, B-2 cells (Winer and Winer 2012). B-1 
cells are further divided into B-1a cells which produce the majority of natural IgM and B-
1b cells which are involved in the T cell-independent antigen humoral response 
(Rothstein, Griffin et al. 2013). B-2 cells, on the other hand, respond to T cell dependent 
antigens. Another subset of B cells, the B-10 cells are IL-10 producing B cells which are 
part of a larger subset called B regulatory cells (Bregs) (Iwata, Matsushita et al. 2011).  
Much of what is known regarding the role of B cells in type 2 diabetes and visceral fat 
inflammation is derived from DIO mice studies. B cells are known to be involved in type 
2 diabetes because B cell deficient DIO mice have increased insulin sensitivity (Winer, 
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Winer et al. 2011). In the lean state, adipose natural B regulatory cells (Breg and B-10), 
in addition to spleen derived B-10 and B-1a cells are known to secrete IL-10 and protect 
against insulin resistance (Nishimura, Manabe et al. 2013, Shen, Yen Chng et al. 2014, 
Wu, Parekh et al. 2014). However, during obesity, the total number of B cells increases in 
VAT, as well as the amount of pro-inflammatory B-2 cells (Duffaut, Galitzky et al. 2009, 
Winer, Winer et al. 2011). Transfer of B-2 cells from DIO mice to DIO B cell null mice 
deteriorates metabolic status (Winer, Winer et al. 2011). It has been shown that there is 
increased class switching of B cells to IgG and that transfer of IgG from DIO mice, but 
not from lean mice, worsens insulin resistance (Winer, Winer et al. 2011). In addition, B 
cells induce MHC dependent secretion of cytokines from T cells such as IFN-γ, which 
can polarize macrophages to a pro-inflammatory M1 phenotype. Although less about the 
role of B cells in type 2 diabetes in humans is known, Winer et al.. has shown that 
distinct profiles of autoantibodies are associated with insulin resistance (Winer, Winer et 
al. 2011, Winer and Winer 2012). Additionally, B cells from type 2 diabetics secrete less 
IL-10 in response to TLR2, 4, or 9 stimulation (Jagannathan, McDonnell et al. 2010). 
However, B cells do not induce insulin resistance on their own. Transfer of B cells from 
DIO mice to DIO mice lacking both T and B cells has little effect on glucose tolerance 
(Winer, Winer et al. 2011). Therefore, much of B cells’ role in type 2 diabetes may be 
mediated through T cell dependent mechanisms.  
 
Other Immune Cells 
 The immune system is very complex, and although much research regarding 
obesity-induced inflammation has been focused on B cells, T cells, and macrophages, a 
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host of other cellular players have been implicated. Neutrophils have been shown to 
transiently migrate into VAT and inhibition of neutrophils improves obesity-induced 
insulin resistance and macrophage accumulation (Elgazar-Carmon, Rudich et al. 2008, 
Talukdar, Oh da et al. 2012). In addition, obesity in response to a high fat diet increases 
neutrophil infiltration within a week (Talukdar, Oh da et al. 2012). These results suggest 
that, similar to a classic immune response, neutrophils are one of the first cells recruited 
to the site of “infection” (Lee and Lee 2014). Eosinophils produce the majority of IL-4 in 
VAT during the lean state. This IL-4 has been shown to be critical in polarizing 
macrophages to the M2 phenotype in M2-GFP reporter mice (Wu, Molofsky et al. 2011). 
Conversely, obesity decreases the number of eosinophils in the adipose tissue indicating 
that this cell type may be involved in regulating macrophages during obesity-induced 
inflammation. Mast cells, although strongly associated with allergy and asthma, have 
been shown to be important in obesity-induced insulin resistance. Deletion of mast cells 
in a high fat diet mouse model improves insulin resistance and reconstitution of mast 
cells worsens it. However, reconstitution of mast cells in IL-6 or IFN-γ knock out DIO 
mice did not worsen insulin resistance. This data indicates that IL-6 or IFN-γ made by 
mast cells in VAT are important to the development of insulin resistance (Liu, Divoux et 
al. 2009). NKT cells, which generally recognize lipid antigens presented on CD1d 
molecules, are found to be increased in VAT in response to a high fat diet in mice within 
6 weeks (Ohmura, Ishimori et al. 2010). However, CD1d deficient mice present no 
differences in insulin resistance and glucose intolerance (Mantell, Stefanovic-Racic et al. 
2011). Several studies have published contradictory results regarding the role of NKT 
cells in obesity-induced inflammation. Therefore, more research is necessary to 
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investigate the role of NKT cells and other cellular players in the development of VAT 
inflammation. 
 
Systemic Inflammation in Type 2 Diabetes 
Chronic inflammation due to obesity does not only affect the VAT. Increased 
secretion of pro-inflammatory cytokines by immune cells in the adipose tissue also 
causes systemic inflammation and insulin resistance in muscle tissue. A summary of 
these cytokines changes are presented in Figure 2. Although many cytokines and 
chemokines are involved in obesity-induced inflammation, TNF-α, IFN-γ, IL-6, and 
especially IL-1β have been closely linked to systemic insulin resistance. 
 
TNF-α 
TNF-α was the first pro-inflammatory cytokine to be associated with obesity and 
insulin resistance (Hotamisligil, Shargill et al. 1993). TNF-α is known to inhibit 
triglyceride deposition and induce lipolysis (Kim, Tillison et al. 2006, Yang, Zhang et al. 
2011, Jin, Sun et al. 2014). Similar to non-esterified free fatty acids, TNF-α inhibits 
insulin stimulated IRS-1 tyrosine phosphorylation and glucose uptake by GLUT4 
(Lumeng, Bodzin et al. 2007).  
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Figure 2. Summary of cellular and cytokine changes during obesity-induced inflammation. 
 
 
Two studies in patients with rheumatoid arthritis undergoing infliximab 
(monoclonal antibody against TNF-α) therapy showed a rapid beneficial effect on insulin 
resistance and sensitivity (Gonzalez-Gay, Gonzalez-Juanatey et al. 2010, Stagakis, 
Bertsias et al. 2012). However, several follow up studies and other studies using 
neutralizing anti-TNF-α antibodies such as Etanercept did not show any improvement in 
insulin sensitivity (Bernstein, Berry et al. 2006, Ferraz-Amaro, Arce-Franco et al. 2011). 
Although conflicting results have been found using TNF-α as a target for the treatment of 
type 2 diabetes and obesity-induced inflammation, this cytokine is important because it 
introduced a link between inflammation, obesity, and insulin resistance. 
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IFN-γ 
IFN-γ is another pro-inflammatory cytokine shown to be related to insulin 
resistance. Glucose intolerance and insulin sensitivity is increased in IFN-γ deficient DIO 
mice (Rocha, Folco et al. 2008). In addition, IFN-γ reduces insulin-induced uptake of 
glucose in adipocytes and can polarize macrophages to the M1 phenotype (Nathan, 
Murray et al. 1983, Martinez, Sica et al. 2008, McGillicuddy, Chiquoine et al. 2009). 
Lastly, IFN-γ, can induce the expression of T cell and monocyte chemoattractant proteins 
such a RANTES and MCP-1 and 2 from an adipocyte cell line (Rocha, Folco et al. 2008).  
 
IL-6 
IL-6 is a classical pro-inflammatory cytokine that has also been implicated in 
metabolic inflammation. In obesity, IL-6 is increased (Pal, Febbraio et al. 2014). This 
increased IL-6 is associated with increases in systemic Th17 cells in DIO mice (Winer, 
Paltser et al. 2009). Although the role of IL-6 in insulin resistance is controversial, it has 
been targeted as potential treatment for metabolic inflammation. For example, 
rheumatoid arthritis patients with diabetes experienced an HbA1c drop when treated with 
anti-IL-6 antibody Tocilizumab (Ogata, Morishima et al. 2011). 
 
IL-1β 
IL-1β has recently become the most prominent cytokine attributed with inducing 
insulin resistance. Once IL-1β is produced, it must be processed into its mature form by 
caspase-1, which is activated by the NOD-, LRR- and pyrin domain-containing 3 
(NLRP3) inflammasome.  IL-1β expression is upregulated during obesity and is strongly 
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related to a high fat diet (Table 1). Our laboratory has shown that it is positively 
correlated to the amount of saturated FA intake, specifically dietary PA (Table 1).  
 
Table 1. Serum IL-1β from Hispanic patients with type 2 diabetes (n =7) correlates with 
dietary fat intake. IL-1β was measured in serum samples obtained from participants in the 
En Balance diabetes intervention program and correlated with dietary intake via the 
University of Arizona Southwest Food Frequency Questionnaire (Ojo, Beeson et al. 2010, 
Salto, Cordero-MacIntyre et al. 2011). P-value <0.05 is a significant correlation. 
Variables Spearman Correlation p-value 
 
Total dietary fat intake (g)  
 
0.821 
 
0.023 
Energy (kcal)  0.929 0.003 
Dietary Cholesterol (mg) 0.786 0.036 
Fatty acids saturated (g) 0.857 0.014 
       10:0 Capric acid (g)  0.786 0.036 
       16:0 Palmitic acid (g)  0.893 0.007 
       18:0 Stearic acid (g)  0.821 0.023 
Fatty acids monounsat.(g) 0.821 0.023 
       18:1 Oleic Acid (g)     0.821 0.023 
 
 
Additionally, we have shown that PA directly induces the secretion of IL-1β from 
dendritic cells by binding TLR4 (Chapter 3). Free FAs may also directly activate the 
NLRP3 inflammasome (Legrand-Poels, Esser et al. 2014). High concentrations of 
glucose promote the dissociation of thioredoxin-interacting protein (TXNIP) from its 
inhibitor thioredoxin (TXR) which results in the activation of NLRP3 and the secretion of 
IL-1β from β-cells (Donath and Shoelson 2011). IL-1β induces the production of a wide 
range of cytokines and chemokines  implicated in insulin resistance and type 2 diabetes 
such as CC-chemokine ligand 2 (CCL2), CCL3 and CXC-chemokine ligand 8 (CXCL8) 
20 
(Donath and Shoelson 2011). These chemokines lead to the recruitment of macrophages. 
Because of IL-1β’s role in insulin resistance and obesity-induced inflammation, it has 
become the target of several clinical trials. Therapeutics against IL-1β show promise for 
treating type 2 diabetes. Patients with type 2 diabetes who were treated with Anakinra, 
Interleukin-1 receptor antagonist (IL-1Ra), for 13 weeks had reduced HbA1c, reduced 
systemic IL-6, IL-17, and C-reactive peptide, and increased secretion of C-peptide 
(Larsen, Faulenbach et al. 2007). These effects lasted up to 39 weeks post withdrawal 
from the medication (Larsen, Faulenbach et al. 2009). However, insulin sensitivity did 
not change, although blocking IL-1 improved β-cells function and reduced markers of 
systemic inflammation. 
  
Novel Concepts in Diet-induced Inflammation and Type 2 Diabetes 
 It is now widely accepted that type 2 diabetes is more than just a metabolic 
disease. Insulin resistance seems to be driven by high fat diets and obesity in an 
inflammation dependent manner. The involvement of adipocyte MHCII and Fc receptors 
(FcRs), autoantibody signatures, and restricted T cell repertoires in obese VAT suggests 
that inflammation associated with insulin resistance is not non-specific (Palming, 
Gabrielsson et al. 2006). Clearly, the net pro-inflammatory environment in obese VAT 
(IL-1β, IL-12, IL-18, and TNF-α) favors a Th1 response. Th1 and CD8+ T cells induce 
and perpetuate macrophage activation during obesity-induced inflammation and B cells 
support this inflammation by secreting antibodies which can activate macrophage FC 
receptors (Winer, Winer et al. 2011, Winer and Winer 2012). The emerging role of 
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specific responses from the adaptive immune system suggests that antigen presenting 
cells may play a key role in the development of obesity-induced inflammation.  
Dendritic cells, professional antigen presenting cells which activate naïve T cells, 
have been used to demonstrate how constituents of a high fat diet, namely palmitic acid, 
could directly contribute to insulin resistance and obesity-induced inflammation. Palmitic 
acid was shown to elicit a robust IL-1β response from dendritic cells in a TLR4 
dependent manner (Chapter 3). The pro-inflammatory cytokine IL-1β can induce insulin 
resistance by affecting insulin receptor phosphorylation and insulin receptor substrate 1 
expression (Jager, Gremeaux et al. 2007). In addition, there is now evidence that FAs 
could directly stimulate the inflammasome, also important in the development of insulin 
resistance and type 2 diabetes (Esser, Legrand-Poels et al. 2014, Legrand-Poels, Esser et 
al. 2014, Moon, Lee et al. 2015). 
Until recently, the mechanism by which saturated FAs activate TLR4 has been 
elusive. Our laboratory has recently demonstrated that PA is an actual TLR4 ligand 
(Chapter 3). Further research will be necessary to determine which other saturated FAs 
can bind TLR4 in addition to understanding how polyunsaturated fatty acids block TLR4 
signaling (Lee, Sohn et al. 2001, Legrand-Poels, Esser et al. 2014). Lastly, the emerging 
role of B cells and antibodies in obesity-induced inflammation leads to the concept that 
diet and lipids may affect B cell function in type 2 diabetes (Winer, Winer et al. 2011). 
Our laboratory recently identified IgG antibodies in human serum that can recognize non-
esterified saturated FAs (Chapter 5). These antibodies appear to be elevated and more 
frequent in populations with unmanaged diabetes. Although the role of these antibodies 
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are unknown, their presence indicates lipids may somehow be involved the immune 
responses seen in type 2 diabetes. 
. 
Summary and Conclusion 
It has long been understood that a high fat diet plays a large role in the 
pathogenesis of type 2 diabetes. More recently, we are beginning to understand that diet 
and obesity can have a direct effect on inflammation associated with type 2 diabetes. 
However, interactions between the constituents of the foods we eat and our immune 
system are poorly understood. Non-esterified long chain saturated FAs such as PA are 
associated with obesity, insulin resistance, and inflammation. It is now clear that 
saturated fatty acids have the potential to act directly on immune cells and induce a 
cascade of events that ultimately contributes to insulin resistance. It is imperative to 
better understand the mechanisms by which free fatty acids interact with the immune 
system in order to design effective therapeutics for obesity-induced inflammation and 
type 2 diabetes. 
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CHAPTER TWO 
A ROLE FOR EPIGENETIC REPROGRAMMING DURING HUMAN 
MONOCYTE DIFFERENTIATION TO DENDRITIC CELLS (PUBLISHED IN 
THE JOURNAL OF CELLULAR AND MOLECULAR PROTEOMICS, 2015) 
Abstract 
Recruitment of monocytes to visceral adipose tissue and their subsequent 
differentiation is an important event in obesity-induced inflammation. Epigenetic 
reprogramming is thought to play an important role during monocyte differentiation into 
dendritic cells. To further understand the regulators of this differentiation process, we 
characterized monocytes and monocyte-derived dendritic cells with mass spectrometry 
based protein/histone expression profiling. Our data show that linker histone H1 proteins 
are significantly downregulated during monocyte differentiation.  While highly enriched 
H3K9-methyl/S10-phos/K14-acetyl tri-modification forms of histone H3 were identified 
in monocytes, they were dramatically reduced in dendritic cells.  In contrast, histone H4 
K16 acetylation was found to be markedly higher in dendritic cells than in monocytes. 
We also found that global hyperacetylation generated by the nonspecific histone 
deacetylase HDAC inhibitor Apicidin induces monocyte differentiation. Together, our 
data suggest that specific regulation of inter- and intra-histone modifications including 
H3 K9 methylation, H3 S10 phosphorylation, H3 K14 acetylation, and H4 K16 
acetylation must occur in concert with chromatin remodeling by linker histones for 
differentiation of human myeloid cells into dendritic cells. Understanding this process 
may lead to therapeutics which can manipulate monocyte differentiation and the obesity-
induced inflammatory response.   
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Introduction 
 
In type 2 diabetes, the number of dendritic cells (DCs) in adipose tissue is 
increased (Lee and Lee 2014). This increase in DCs is likely due to the recruitment of 
monocytes and subsequent differentiation in response to adipose tissue inflammation, 
similar to what occurs during colitis (Rivollier, He et al. 2012). Differentiation of 
monocytes from human peripheral blood mononuclear cells (PBMC) into dendritic cells 
using GM-CSF + IL-4 has frequently been used as a model for understanding the process 
of dendritic cell immune responses to inflammatory stimuli, viral infection, and 
environmental cues (Takashiba, Van Dyke et al. 1999, Baek, Haas et al. 2009, Fangradt, 
Hahne et al. 2012). In human bone marrow, myeloid progenitors give rise to 
macrophage/dendritic cell progenitor cells from which are derived monocytes, 
macrophages, and dendritic cells. However, epigenetic regulation or reprogramming in 
this complex differentiation system is not yet fully understood. 
Previous studies demonstrated that histone H1s are differentially expressed and 
incorporated into chromatin during embryonic stem cell differentiation and 
reprogramming to pluripotency (Terme, Sese et al. 2011).   The linker histone H1s 
"beads-on-a-string" structure aids chromatin folding into highly compacted 30 nm 
chromatin fibers (Misteli, Gunjan et al. 2000).  In addition, the three histone H1 isoforms, 
H1.3, H1.4 and H1.5, are required for embryonic stem cell differentiation as 
demonstrated by in vivo H1.3/H1.4/H1.5 triple null experiments (Zhang, Cooke et al. 
2012).  Histone H1 null cells exhibit altered nucleosome architecture (Hashimoto, 
Takami et al. 2010) which may cause epigenetic reprogramming (Terme, Sese et al. 
2011), specific changes in gene regulation including repression of pluripotency gene Oct4 
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expression (Fan, Nikitina et al. 2005, Zhang, Cooke et al. 2012), and cell growth (Fan, 
Nikitina et al. 2003, Sancho, Diani et al. 2008).  In our experiments, CD14+ monocytes 
were treated with GM-CSF + IL-4.  After treatment, monocyte differentiation into 
dendritic cells was assessed by mass spectrometry and bioinformatics analyses. 
          In this chapter, we describe unique protein expression profiles, specifically the 
linker histones, between monocytes and dendritic cells. We identified H3K9-methyl/S10-
phos/K14-acetyl tri-modification forms in monocytes, but not in dendritic cells.  In 
addition, histone H4 K16 acetylation was low in monocytes but significantly higher in 
dendritic cells. Our findings suggest that monocyte-to-dendritic differentiation involves a 
switch from H3 tri-modification and high linker histone expression to histone H4 K16 
acetylation and reduced histone H1. 
 
Materials and Methods 
Monocyte Isolation, Differentiation, and Flow Cytometry Analysis 
Peripheral blood from healthy adult donors (age 18+) were collected from plasma 
apheresis filters from Lifestream blood bank, San Bernardino, CA, according to Loma 
Linda University IRB requirements. Leukocytes were obtained by lysing the red blood 
cells using ACK lysis buffer (8.3g/L NH4CL, 1.0g/L KHCO3, 3.7mg/L EDTA Na) 
according to standard protocol (Life Technologies). CD14+ cells were isolated from the 
leukocyte fractions with anti-CD14 micro beads (MACS, Miltenyi biotech). 
         Monocytes were cultured in RPMI 1640 supplemented with 10% FBS at a density of 
106 cells per 1 mL. In parallel, monocytes were cultured in RPMI 1640 media with 
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50ng/mL GM-CSF + 10ng/mL IL-4 for 6 days to obtain dendritic cells, respectively 
(Figure 3).  Monocytes were also cultured in 1µM Apicidin (Santa Cruz Biotechnology).  
 
 
Figure 3. A brief outline of the myeloid cell differentiation process and the differentiation 
strategies adopted in this study. 
 
 
 Cells were stained for flow cytometry with the following antibodies (Ab): anti-CD14 
APC (Miltenyi), anti-CD11b PE, anti-H1.5 (Abcam), anti-H4K16Ac (Abcam), anti-
H3K9Me3, anti-H3S10p, anti-H3K9Me3S10pK14Ac, anti-Rabbit IgG FITC (Biolegend), 
anti-HLA-DR PerCP (Beckton Dickenson), and fixable viability dye eFlour 450 
(eBioscience) according to standard protocol. For intracellular histone staining, cells were 
fixed with 4% paraformaldehyde for 10 min, permeabilized with Odyssey blocking buffer 
(Licor Inc.) + 0.2% Triton-X 100, then stained with 1°Ab followed by the 2°Ab at room 
temperature for 45 min each. Cells were then washed with PBS and resuspended in 195 
µl PBS + 5 µl Propidium Iodide (eBioscience) + 50µl/mL RNAse. Cells were run on a 
MACSQuant flow cytometer and data was analyzed using FlowJo software v.7.6 (Tree 
Star, Ashland, OR). 
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Sample Preparation and Mass Spectrometry Analysis 
 The cell pellet was lysed in RIPA lysis buffer (Santa Cruz Biotechnology, CA) with 
additionally added 1% Nonidet P40, PMSF (0.2mM), and protease inhibitor cocktail 
(Roche, one tablet per 10 mL) with the assistance of sonication (3 x 30 strokes) and 
incubation on ice for 2 hours. The protein mixture was centrifuged and the supernatant 
transferred into a clean tube. This extraction procedure was carried out twice and the 
supernatants were combined. The protein concentration in the supernatant was 
determined by BCA assay.  Approximately 60 µg of each protein sample was 
resuspended in 25mM triethylammonium bicarbonate, pH 7.8.  The protein solution was 
reduced by addition of 10 mM DTT and incubation at 50 ºC for 30 min, followed by 
carbamidomethylation with 25 mM iodoacetamide in the dark for 1 hr.  The proteins 
were precipitated by addition of 4 volumes of -20 ºC precooled acetone and stored at -20 
ºC overnight. The protein was pelleted by centrifugation at 14,000 rpm for 10 minutes 
and the supernatant was discarded.  The protein pellet was dissolved in 25 mM 
triethylammonium bicarbonate buffer and digested by trypsin at a protein/trypsin enzyme 
ratio of 25:1 (by mass) for 10 hours at 37 ºC.   The TMT (Tandem Mass Tag) isobaric 
Mass Tagging Kit (Thermo-Fisher Scientific) was used to label the peptides following the 
manufacturer’s recommended conditions. Each TMT-labeled protein pool was acidified 
with 0.1% formic acid and fractionated with strong cation-exchange (SCX) 
chromatography on a Toptip column (Poly LC, MD). For fractionation, the matrix was 
equilibrated with 0.1% formic acid in 20% acetonitrile (ACN) to facilitate peptide 
binding.  After collection of the flow-through, 1 mL of each subfraction was sequentially 
eluted with 20% ACN, 0.05M KCl, 0.2M KCl, 0.35 M KCl, 0.5M KCl, and 5% 
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ammonium hydroxide in 20% ACN.  Next, the fractions were dried under vacuum to 
remove ACN, reconstituted in 1% formic acid, and then desalted using a Toptip column 
with C18/hypercarb mixed materials (Poly LC, MD).  The eluted peptides were once 
again vacuum-dried, reconstituted in 30 μl of 0.1% formic acid, and then subjected to 
LC-MS/MS analysis. Quantitation of SCX fractionated TMT-6 labeled peptides was 
carried out on the Thermo LTQ-Orbitrap Velos Pro mass spectrometer.  Peptides were 
separated by online reverse phase liquid chromatography (RPLC) using an Easy-nLC 
equipped with an autosampler (Thermo Scientific).  A 10 cm, 75 μm id (internal diameter 
of the column), 3-μm particle size, C18-A2 analytical column (Thermo) was used for the 
RPLC separations.  Approximately 2 μg of peptide sample was injected.  A precolumn 
(Thermo, 0.1 × 2 cm, 5 μm C18-A1) was brought in line with the analytical column and a 
250-min gradient (solvent A, 0.1% FA in water; solvent B, 0.1% FA in ACN) from 5–
30% solvent B was used for separating the peptides.  The Orbitrap mass analyzer was set 
to acquire data at 60,000 FWHM resolution for the parent full-scan mass spectrum 
followed by data-dependent high collision-energy dissociation (HCD) MS/MS spectra for 
the top 12 most abundant ions acquired at 7500 resolution.   
 
Data Analysis 
Proteins were identified and quantified through the Proteome Discoverer 1.3 
platform (Thermo) by using both Mascot searching engine (Mascot Darmon 2.2.2; Matrix 
Science, London, UK) and Sequest HT (employing the International Protein Index (IPI) 
Homo Sapiens database (version 3.73, June 2010, containing 89739 entries).  Mascot (or 
Sequest) searching parameters were used as follows: Carbamidomethylation of cysteine 
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and TMT-6 modification of peptide N-terminus and lysine were set as fixed 
modifications and oxidation of methionine and deamination of asparagine and glutamine 
were set as variable modifications, trypsin was the protease selected and up to two missed 
cleavages was used.  Mass tolerance for the precursor ions was 10 ppm and for the 
MS/MS 0.2 Da.  Only peptides with minimal length of four amino acids were considered 
and peptides were filtered for maximum false discovery rate of 1%.  At least one unique 
peptide with posterior error probability of less than 0.05 was accepted for quantification 
using the TMT-reporter ions and proteins were grouped.    
 
Bioinformatic Analysis 
Multivariate statistics analysis using the “R” program has previously been utilized 
for metabolic profiling (Reitman, Jin et al. 2011).  We have adapted this method for 
protein expression statistics analysis. Multivariate statistics and associated graphics were 
performed in R, version 64.25.1. Heat maps were drawn using the heatmap.2 function 
found in the gplots package. Ingenuity Pathway Analysis (IPA) of protein 
functions/pathways or upstream regulators was performed using individual or the 
combined protein expression dataset from two monocyte GM-CSF treatment 
experiments. The activation z-scores (a numerical value representing the strength of the 
relationship between a set of proteins and a function/disease) of “Cell movements” and 
“Functions for Hematological System Development” from IPA analysis were extracted 
for multivariate statistics analysis to determine cell motility patterns associated with cell 
differentiation.  Principal component analysis (PCA) was performed using the prcomp 
function in R and the calculation was based upon a singular value decomposition of the 
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centered and scaled data matrix.  The first two principal components, PC1 and PC2, 
which contributed to the majority of the variance in the dataset, were plotted using the 
built-in biplot function.  
 
Statistical Analysis 
Determination of statistical significance of histone H1 expression among 
treatment groups was completed using two-way ANOVA in GraphPad Prism v6. For 
TMT measurement of Histone H1s, five biological replicates were performed. A web 
based Java code based on the Sattherwaite equation (Zhang, Schrag et al. 2012) was 
written for calculation of the degrees of freedom (v or DF) and t-values that were used for 
calculation of p-values. Significance was accepted at p = 0.05.  In figures, * = p < 0.05, 
** = p < 0.01, *** = p < 0.001, and **** = p < 0.0001. 
 
Antibody Generation 
A rabbit polyclonal antibody against histone H3 K9Me3S10pK14Ac was made as 
described (Xu, Zhang et al. 2005) using a synthetic peptide containing histone H3 
sequence: KQTAR(K-Me3)(S-Pho)TGG(K-Ac)APRKQC. Specificity of this anti-H3 tri-
modification antibody was further tested by ELISA (data not shown). 
K9Me3S10pK14Ac peptide was conjugated to KLH as described by the manufacturer 
(Pierce) and coated to the microtiter plates. The specific or nonspecific H3 competitor 
peptides were tested in the competition assay for their ability to inhibit binding of anti-H3 
tri-modification antibody to K9Me3S10pK14Ac-KLH conjugate. 
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Results 
Analysis of Protein Expression in Differentiated Monocytes 
Monocytes isolated by CD14+ magnetic beads were differentiated into dendritic 
cells (DC) in culture using interleukin-4 (IL-4) (10ng/mL) + GM-CSF (50ng/mL) for 6 
days (Figure 3). The cells were stained for flow cytometry with anti-CD14 and anti-
CD11b (integrin alpha M) to ensure greater than 97% CD14+ monocyte isolation purity 
and the success of differentiation (Figure 4).  
 
 
 
Figure 4. Quantification of surface CD11b on treated monocytes by flow cytometry. Fold 
change in MFI was determined by subtracting out the background fluorescence and 
normalizing data to monocyte surface expression. N=4. 
 
 
Next, whole cell lystates of monocytes and DCs were made for analysis by mass 
spectrometry. The whole cell lysates were rich in nuclear proteins due to stringent 
extraction conditions. These conditions included the use of RIPA buffer with additional 
1% NP-40 and extensive sonication to shear chromatin.  Under these conditions, nearly 
complete extraction of nuclear proteins was achieved as attested by the presence of 
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histone H1.5 in the whole cell protein extracts but not in the remaining pellets which 
underwent acid-precipitation (Figure 5A).  Histone proteins were abundant in the cell 
extracts and sequence coverage by mass spectrometry for most histones was over 90% 
(Figure 5B).  
Equal amounts of proteins extracted from the cell lysates were digested by trypsin 
and labeled with TMT reagents.  About 1551 proteins were identified and quantified in 
two sets of monocytes and DCs.  Because there are distinctive surface marker/cytokine 
gene or protein expression profiles detected for GM-CSF + IL-4-treated monocytes 
(dendritic cells) as indicated by previous genomic or flow-cytometric (FC)  analysis (Le 
Naour, Hohenkirk et al. 2001, Seager Danciger, Lutz et al. 2004), we assessed markers 
typically used for characterization of human monocyte-derived dendritic cells. Our mass 
spectrometry data revealed that protein expression of CD209 (DC-SIGN) and CD1a was 
increased by 12.0 and 2.9 folds in GM-CSF + IL-4-treated monocytes while the 
expression of CD14 was decreased by 2.9 fold. The protein expression profiles of these 
three proteins measured by mass spectrometry were in agreement with previously 
demonstrated FC and gene expression data of GM-CSF + IL-4 induced dendritic cells.  
After confirming with flow cytometry and mass spectrometry that the differentiated cells 
were dendritic cells, we then used Ingenuity Pathway Analysis (IPA) to evaluate 
proteome differences between monocytes and dendritic cells. IPA indicated that 
pathways involving cell movement and hematological system development and function 
are differentially regulated for dendritic cells as compared to monocytes.  
 
 
33 
 
Figure 5. Extraction efficiency of histone proteins from whole cell lysates by 
modified RIPA buffer.  (A) Western-blot analysis of histone H1.5 in the RIPA cell lysates 
as compared with extraction of histones extracted by acid-precipitation (AP) from the cell 
pellets which remained after RIPA extraction.  The volume of acid-extraction solution was 
adjusted to the same volume of RIPA extraction. Two separate extraction experiments were 
performed and U937 cells were used as a test. (B) Typical protein sequence coverage of 
major histone proteins were achieved from the proteomics experiments carried out in this 
study. 
 
 
Since the proteins regulated in these two pathways are related to cell motility, the 
activation z-scores from IPA analysis from these two pathways were extracted to create a 
heat map (Figure 6).  Analysis of this sub-dataset suggests that monocyte-derived 
dendritic cells showed less adhesion of immune cells, neutrophils, and phagocytes, but 
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faster cell movement and migration, and higher levels of phagocytosis of myeloid cells in 
comparison with monocytes (Figure 6A).  Therefore, activation z-scores of cell motility 
could be used to distinguish between monocytes and DCs. These results support findings 
that suggest differentiation from monocytes into DCs is accompanied by a significant 
change in the expression of genes related to cell structure and motility (Hashimoto, 
Suzuki et al. 1999). 
In addition to DC markers, other proteins implicated in monocyte-to-dendritic cell 
differentiation were quantified by mass spectrometry. Fatty acid binding protein 4 
(FABP4) was significantly up-regulated (4 fold) in GM-CSF + IL-4-treated monocytes. 
Other significantly increased upstream regulators specific to GM-CSF + IL-4-treated 
cells include immunoglobulin, β-estradiol, PPARγ, TGFβ, and TP53.  These transcription 
factors have been shown to act cooperatively in the regulation of cell cycle progression 
and monocyte-derived DC differentiation (Nagy, Szanto et al. 2012, Zietara, Lyszkiewicz 
et al. 2013). 
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Figure 6. Selective protein expression profile in cell motility of DCs compared to 
monocytes. Heat map of the z-scores of 33 types of cellular functions related to cell 
motility. Datasets from IPA analysis of GM-CSF + IL-4-treated monocytes are plotted.  
 
 
Correlation between Histone H1 Expression and Cell Lineage 
Principal component analysis of changes in the dendritic cell proteome identified 
six proteins which negatively correlated with monocyte differentiation (data not shown). 
These proteins include histone H1.4, histone H1.5, and high mobility group protein 
HMG-17. As detected by mass spectrometry, these proteins were representative of the 
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most significantly downregulated proteins in response to differentiation.  Since extremely 
altered expression of HMG-17 and H1.4/H1.5 linker proteins was observed in 
differentiated cells, we extracted the quantified expression levels of all the linker histone 
proteins.   
We found that HMG-17 and histone H1 isoforms (H1.0, H1X, H1.2, H1.3, H1.4, 
and H1.5) were significantly downregulated in GM-CSF + IL-4-differentiated cells 
(Figure 7).  The data suggest that DCs have a unique histone H1 expression profile which 
possibly affects the degrees of plasticity of chromatin structures confined by the linker 
histone proteins.  Presumably, cells with low levels of histone H1 expression have 
loosely confined chromatin structures that could affect cell morphology and potentially 
cell motility. Loosely confined chromatin would have increased chromatin accessibility 
to transcription factors and histone modification enzymes including histone 
acetyltransferases.  
 
Changes in Histone Modifications during Monocyte-to-Dendritic Cell Differentiation 
Due to the observed changes in histone H1 expression levels, we set out to 
determine whether histone modifications were affected. The same set of mass 
spectrometry data for protein expression analysis was reanalyzed by resetting the 
searching parameters including removal of TMT-6 labeling to lysine but addition of 
dynamic modification of acetylation and methylation to lysine and phosphorylation to 
serine and threonine.  Under these new search parameters, protein acetylation and 
phosphorylation sites were identified and specific attention was paid to histone 
modifications.  We found that most of the major histone proteins were identified and 
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quantified with higher than 90% sequence coverage (Figure 4B). Mascot searching 
reported the identification of two H3 peptide sequences with K9-dimethylation/S10-
phosphorylation/K14-acetylation and K9-trimethylation/S10-phosphorylation/K14-
acetylation (H3K9-dimethyl, H3K14-acetyl, and H3S10-phos). Significant amounts of 
H3K9-dimethyl/K14-acetyl di-modification and H3K9-acetyl/K14-acetyl forms were also 
detected.  After detecting these and other post-translational modifications (PTMs), we 
assessed their relative levels in monocytes and dendritic cells. 
 
 
Figure 7. Comparison of relative histone expression between monocytes and dendritic cells 
(GM-CSF + IL-4 treated monocytes) N=5.  Statistical analysis - Determination of statistical 
significance among treatment groups was completed using Two Way ANOVA in 
GraphPad Prism v6. Significance was accepted at p = 0.05.  In figures, * = p < 0.05, ** = 
p < 0.01, *** = p < 0.001, and **** = p < 0.0001. 
 
 
As indicated in Figure 8, histone H4K16Ac was significantly higher in dendritic 
cells than in monocytes (Figure 8).  We used intracellular staining and flow cytometry to 
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validate this PTM in addition to other PTMs identified by mass spectrometry. 
 
 
Figure 8. Higher-energy collisional dissociation (HCD) spectra of TMT tagged H4K16Ac 
peptide. HCD spectrum of the precursor ion at m/z 380.2356 (2+) corresponding to H4 K16 
acetylated peptide.  Tryptic peptides of monocyte proteins were labeled with TMT-126 and 
-127 and dendritic cells (GM-CSF+IL-4 treatment) were TMT-130 and -131. 
 
 
Using an antibody we generated against the H3K9Me3S10pK14Ac tri-modification 
(data not shown), along with commercial antibodies against H3K9Me3 (H3 lysine 9 tri-
methylation), H3S10p (H3 serine 10 phosphorylation), H4K16Ac (H4 lysine 16 
acetylation), and histone H1.5, we did FC experiments in order to verify the quantitative 
histone data obtained by mass spectrometry. As shown in Figure 9, H1.5 was highly 
enriched in monocytes (97.5% cells positive) and dramatically reduced in dendritic cells 
(4.82%) displaying a pattern similar to our mass spectrometry data (data not shown).  
Similarly to H1.5, H3S10p was also highly enriched in monocytes (98.3% cells positive) 
and dramatically reduced in dendritic cells (2.28%). The same decreasing pattern was 
seen for H3K9Me3 from monocytes (24.8%) to dendritic cells (1.61%).  Consistent with 
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the mass spectrometry data, H3K9Me3S10pK14Ac tri-modification was enriched in 
monocytes (8.82%) and dramatically reduced in dendritic cells (0.7%). In contrast to 
histone H3 methylation and phosphorylation, H4 lysine K16 acetylation (H4K16Ac) was 
slightly increased in dendritic cells (1.34%) as compared with in monocytes (0.35%), 
which showed the same pattern as the mass spectrometry data (Figure 8).  The data 
revealed that a switch from H3 methylation, phosphorylation, and high linker histone 
expression to histone acetylation occurred during monocyte-to-dendritic cell 
differentiation. 
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Figure 9. Flow Cytometric analysis of cell cycle and expression of histone H1.5 and histone 
modifications in monocytes and dendritic cells generated with GM-CSF +IL-4.  (A) Dot 
plots represent the expression of histone modifications. The x-axis represents propidium 
iodide staining for genomic DNA. The cell population to the left are in G1/G0 phase, and 
the cell population to the right are in G2/M phase with cells in between in S phase. The y-
axis is the fluorescence of 2° Ab against the indicated 1° Abs.  (B) Bar graph (mean ± 
SEM) of the percent of cells positive for histone H1.5 or histone modifications. N=3, 
samples run in duplicates. Statistical analysis was performed using Two-way Anova. 
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Proper Regulation of Histone Acetylation is Required for Monocyte Differentiation 
into Dendritic Cells 
Because we observed that H4 K16 acetylation increased during monocyte 
differentiation with GM-CSF + IL-4 (Figures 7 and 8), we investigated the role histone 
H4 K16 acetylation plays in monocyte differentiation to DCs by treating monocytes with 
1 µM Apicidin in order to manipulate histone acetylation.  Apicidin is a specific 
HDAC3/NCoR histone deacetylase inhibitor (Mazitschek, Patel et al. 2008).  When 
monocyte HL60 cells were incubated with 100 nM Apicidin, global histone acetylation 
increased to the maximum level at 48 hours (Hong, Ishihara et al. 2003).  As expected, 
we detected hyperacetylation of histone H4K16 by both flow cytometry analysis (Figure 
10A) and Western-blot analysis (Figure 10B) until the cells became arrested at the G0/G1 
phase after a six-day incubation (Figure 11) (Han, Ahn et al. 2000).  Brightfield 
microscopy clearly showed that the morphology of Apicidin-treated monocytes was 
distinct from DCs (Figure 12A). The monocyte surface marker CD14 was reduced and 
the macrophage/dendritic cell surface marker CD11b was increased (Figure 12B). 
However, the surface marker CD11c decreased significantly in Apicidin-treated 
monocytes (Figure 12B) revealing a phenotype of CD14medCD11bhiCD11clo which is 
distinguishable from the phenotype of CD14loCD11bhiCD11chi belonging to GM-CSF + 
IL4 (DC) treated monocytes (Figure 12B).  Judged by the cell morphology and the 
expression of cell surface markers (Figure 12), the Apicidin-treated monocytes observed 
in this experiment seemed to begin differentiation but did not completely differentiate 
from monocytes into dendritic cells.   
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Figure 10. Histone acetylation and differentiation. (A) H4 K16 acetylation is involved in 
monocyte differentiation. Bar graph (mean ± SEM) of the percent of cells positive for H4 
K16 acetylation (N=4). Statistical analysis was performed using Two-way Anova. (B) 
Western blot of increasing acetylation at H4K16 in monocytes in response to 1μM Apicidin 
treatment. Approximately 20μg of nuclear lysate as determined by A280 was loaded per 
lane. (C) Acetylation and methylation is associated with CD14, CD11b, and CD11C gene 
expression by analysis of public Geo Expression Omnibus data set (Accession number 
GSE36402). Primary normal adult lymphocytes were used for a ChIP- chip assay. After 
DNA to protein crosslinking, the chromatin was immunoprecipitated with either anti-
H3K9me3, H3K9Ac, or H4K16Ac. Next, the crosslinking was reversed and the DNA 
subjected to tiling DNA array. The control input was sample with no antibody. 
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Figure 11. Inhibition of HDACs arrests differentiating monocytes in the G1/G0 phase of 
cell cycle. (A) Flow cytometry analysis of PI staining of dendritic cells and monocytes in 
the presence or absence of Apicidin after 6 days of differentiation. Histograms represent 
the cell cycle profile. The furthest peak to the left represents G1/G0 phase, the second 
peak represents G2/M phase, and the space in between the peaks represents S phase. (B) 
Quantification of cells in the G2/M phase from panel A. Bar graphs (mean ± SEM) are 
representative of 20 replicates. Statistical analysis was performed using Two-way Anova. 
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Figure 12. Histone hyperacetylation is necessary for proper monocyte differentiation. (A) 
Brightfield 100x microscopy images of dendritic cells and monocytes after 6 days of 
differentiation in the presence or absence of Apicidin. (B) Cells were stained for CD14, 
CD11c, and CD11b. The amount of surface expression of each marker is displayed as the 
geometric mean fluorescence intensity (Geom. MFI) or as percent of cells positive for the 
indicated marker. Bar graphs (mean ± SEM) and microscopy images are representative of 
4 different patient samples in sextuplicate. Statistical analysis was performed using Two-
way Anova.  
 
 
Because hyperacetylation induced by Apicidin seemed to regulate expression of 
DC surface markers, we investigated the association of PTMs with CD11c, CD11b and 
CD14 expression. Analysis of public ChIP-chip microarray data of lymphocytes using 
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anti-H4K16Ac, H3K9Ac, and H3K9me3 showed that these three PTMs differentially 
regulated transcription of CD14, CD11c, and CD11b (Miao, Chen et al. 2012).  
Acetylation of H4K16 specifically increases transcription at the CD11b gene, acetylation 
of H3K9 specifically increases transcription at the CD14 and CD11c genes, and tri-
methylation of H3K9 represses transcription at the CD11c gene but is not tightly 
associated with the CD11b gene (Figure 10C).  An equilibrium among H3K9 tri-
methylation, H3K9 acetylation, and H4K16 acetylation determines the expression levels 
of CD14, CD11b and CD11c (Figure 12)  during monocyte differentiation. Because 
Apicidin non-specifically induces global hyperacetylation of H3 (including K9, K18, and 
K23) and H4 (including K5, K8, K12, and K16) (Han, Ahn et al. 2000), it does not 
induce proper monocyte to dendritic cell differentiation. Therefore, a drug that 
specifically acetylates H4 K16 but deacetylates at the other H3 and H4 sites would be a 
promising agent for monocytes to be differentiated to dendritic cells with the phenotype 
of CD14loCD11bhiCD11chi .   
 
Conclusion and Discussion 
Using TMT-6 labeling and mass spectrometry analysis, we have compared the 
protein expression profiles of human monocytes with dendritic cells generated using GM-
CSF + IL-4.  Clustering analysis using the activation z-scores obtained from IPA 
revealed that monocytes differed substantially from GM-CSF + IL-4 induced dendritic 
cells based upon their cell motility patterns (Figure 6).  These differences may be due to 
differential expression of linker histone proteins, typically histone H1.4 and H1.5 (Figure 
7). H1.4/H1.5 expression was markedly decreased in dendritic cells differentiated from 
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monocytes, suggesting that expression of these proteins might be a dynamic process 
(Figure 7). The linker histone proteins (H1s) define chromatin structures and are 
normally considered to be chromatin repressors (Misteli, Gunjan et al. 2000, Clausell, 
Happel et al. 2009).  Chromatin in monocytes was associated with highly expressed H1s 
and differed from chromatin in dendritic cells which was associated with low levels of 
histone H1 expression.  This effect might be related to chromatin plasticity with a tightly 
confined structure found in the monocytes in comparison with loosely confined structures 
in dendritic cells that might affect cell morphology and cell motility. In macrophages the 
loss of H1 proteins facilitate the chemotactic response to inflammatory stimuli (De Toma, 
Rossetti et al. 2014). Therefore, down-regulation of H1s may play a similar role in DCs 
and be necessary for optimal DC function. 
Unique tri-modification forms, H3K9-dimethyl/S10-phos/K14-acetyl and H3K9-
trimethyl/S10-phos/K14-acetyl, was identified in human monocytes but was absent in 
dendritic cells (Figure 9). This undeniable identification by mass spectrometry was 
consistent with previous identifications of these modifications during mitosis (Garcia, 
Barber et al. 2005), suggesting that H3S10 phosphorylation and H3K9 methylation could 
naturally occur simultaneously (Mateescu, England et al. 2004, Eberlin, Grauffel et al. 
2008, Papamokos, Tziatzos et al. 2012).  Histone H4 K16 acetylation, a key switch for 
turning heterochromatin into euchromatin (Millar, Kurdistani et al. 2004), was low in 
monocytes while significantly increased in dendritic cells (Figure 8 and 7). Clearly, the 
cross-talk between inter- and intra-histone modifications that include H3 K9 methylation, 
H3 S10 phosphorylation, H3 K14 acetylation, and H4 K16 acetylation in concert with 
chromatin remodeling by linker histones is one of the major epigenetic regulatory 
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machineries that regulate the processes of cell cycle progression and differentiation of 
human myeloid cells (Hass, Gunji et al. 1992). Inhibition of histone deacetylase HDAC3 
by Apicidin increased the acetylation of histone H4 K16 and decreased histone H3 K9 
methylation, S10 phosphorylation, and H1.5 expression (data not shown), resulting in 
partial monocyte differentiation (Figure 12).  This PTM pattern suggests histone 
acetylation is required for initial monocyte differentiation.  Apicidin inhibits the 
expression of CD11c (Figure 12B). Therefore Apicidin is not a proper small molecule to 
be used to obtain dendritic cells from monocytes. However, Apicidin could be of benefit 
in the treatment of inflammatory diseases such as type 2 diabetes by arresting cell 
growth.  
The information generated by proteomics analysis on histone modifications and 
the expression of linker histones during human monocyte-to-dendritic cell differentiation 
is a foundation for elucidating epigenetic remodeling/reprogramming mechanisms that 
underlie human myeloid cell differentiation. Here, we have provided a basis for 
understanding the epigenetic mechanisms that control normal differentiation. Future 
research should focus on PTMs associated with high fat diets, obesity, and type 2 
diabetes to understand the role of epigenetic factors that regulate immune cell 
differentiation during chronic obesity-induced inflammation. Studies that assess 
induction of gene expression of key inflammatory cytokines such as TNF-α (Lee, Kim et 
al. 2003, Iwamoto, Iwai et al. 2007) may uncover epigenetic targets that facilitate the 
development of therapeutic agents for the treatment of disorders of the human immune 
system such as type 2 diabetes. Continued development of epigenetic drugs, such as 
histone acetyltransferase activators or histone deacetylase inhibitors that specifically 
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modulate histone H4 K16 acetylation, can open up a new avenue for dendritic cell 
immune therapy. 
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CHAPTER THREE 
PALMITIC ACID INDUCES DENDRITIC CELL MATURATION AND TLR4 
DEPENDENT SECRETION OF IL-1Β  
Abstract 
 Palmitic acid (PA) stimulates pro-inflammatory responses in human professional 
antigen presenting cells such as dendritic cells (DCs). Here we show PA stimulates 
human DC maturation and activation as determined by the upregulation of CD86 and 
CD83. Using isothermal titration calorimetry, we show that PA binds to Toll-like 
receptor 4 (TLR4). The binding of PA stimulates TLR4 endocytosis, confirming that PA 
is a TLR4 ligand. In addition, we show that PA induces TLR4 and caspase-1 dependent 
secretion of active IL-1β. Lastly, our data show that the activation of NFκB by PA is 
regulated by both TLR4 signaling and PA generated reactive oxygen species. These 
experiments demonstrate for the first time that activation of TLR4 depends on molecular 
interactions between PA and TLR4. These findings provide a mechanism for PA action 
on cells of the innate immune system.  
 
Introduction 
 Fatty acids (FAs) are potent regulators of immune function. For example, omega 
3/6 polyunsaturated FAs are anti-inflammatory while saturated FAs stimulate 
inflammation (Weatherill, Lee et al. 2005) . Although lipids influence inflammation, 
mechanisms defining how FAs modulate immune cells remain unknown. Current theories 
include active FA metabolites, alteration of cell membrane composition, FA 
peroxidation, and more recently, receptor responses (Hirasawa, Hara et al. 2008, 
50 
Leonarduzzi, Gamba et al. 2012, Shaikh, Jolly et al. 2012). Although much progress has 
been made in understanding FA-induced inflammation, research regarding FA effects on 
immune cells, specifically dendritic cells (DCs), is sparse. 
  Dendritic cells are responsible for conveying innate immune signals to 
lymphocytes. Because DCs are professional antigen presenting cells which bridge innate 
and adaptive immunity, it is important to understand how they process various classes of 
stimuli. In innate immunity, the DC response to inflammation comprises secretion of 
TNF-α and NO to aid in the clearing of pathogens (Serbina, Salazar-Mather et al. 2003). 
DCs also activate NK cells through both contact dependent and independent mechanisms 
(Barreira da Silva and Munz 2011). In adaptive immunity, DC-secreted factors affect IgA 
production by B cells (Tezuka, Abe et al. 2007). Most importantly, DCs prime naïve T 
cells, stimulate Th1 and Th2 responses, cross present Ag to CD8+ T cells, and regulate T 
cell differentiation (Nakano, Lin et al. 2009, Segura, Albiston et al. 2009). 
 The DCs ability to interact with T cells depends on its maturation state. Immature 
DCs are highly endocytic and express relatively low levels of T cell co-stimulatory 
markers and MHC (Steinman and Swanson 1995, Mellman and Steinman 2001). In 
contrast, mature DCs express proteins important for T cell activation and have reduced 
antigen uptake, accompanied with efficient Ag presentation (Cella, Engering et al. 1997). 
Phenotypically, high expression of CD83 is the best measure of DC maturity (Lechmann, 
Berchtold et al. 2002). 
 Only mature DCs interact with T cells. Whether this interaction induces tolerance 
or immunity depends on DC activation. Activation is a process distinct from maturation. 
Activated DCs can be distinguished from resting mature DCs by expression of higher 
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levels of MHC and co-stimulatory molecules and by production of cytokines (Probst, 
Lagnel et al. 2003).   
Palmitic acid (PA), a long chain saturated FA prevalent in the Western diet, may 
activate innate immune cells through TLR4.  For example, PA activation of microglia is 
inhibited by TLR4 neutralizing antibodies and dietary FAs activate TLR4 signaling in 
macrophages and increase TLR4 dimerization (Shi, Kokoeva et al. 2006, Wong, Kwon et 
al. 2009, Wang, Liu et al. 2012). Furthermore, Lee et al. showed that saturated FAs did 
not activate NFκB in TLR4 negative macrophage cell lines (Lee, Sohn et al. 2001). While 
there is strong evidence that PA regulates immune cells through TLR4, no studies have 
yet demonstrated molecular interactions between FAs and TLR4.  
 Evidence suggests that FAs may contribute to production of  IL-1β (Grishman, 
White et al. 2012). IL-1β is produced as a pro-protein in response to NFκB activation 
through pattern recognition receptor (PRR) signaling. However, translation of IL-1β is 
not sufficient for secretion. A second signal from a PAMP or DAMP, such as reactive 
oxygen species (ROS) or TRIF/TRAM dependent TLR signaling, must induce pro-
protein cleavage. This second signal induces the formation of the inflammasome, a 
multimeric protein complex. Inflammasomes typically consist of a sensor molecule, an 
adaptor protein (ASC), and caspase-1(Latz, Xiao et al. 2013). The sensor molecule for 
most inflammasomes is a NOD-like receptor (NLR) such as NLRC4 (NOD-, LRR- and 
CARD-containing 4) (Ting, Lovering et al. 2008). When pro-caspase-1 is recruited to the 
ASC via homotypic binding of CARDs (caspase activation and recruitment domains) 
(Lopez-Castejon and Brough 2011), autolytic cleavage occurs, producing active caspase-
1. Caspase-1 then cleaves pro-IL-1β into active of IL-1β  (Latz, Xiao et al. 2013).  
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 Because DCs express TLR4 and play key roles in both innate and adaptive 
immune responses, PA has the potential to exert broad immune effects.  Therefore, our 
goal was to characterize PA-induced DC maturation and activation.  We hypothesized 
that PA ligation to TLR4 causes DCs to adopt a pro-inflammatory phenotype. Our 
isothermal titration calorimetry (ITC) data show that PA binds TLR4 via the adaptor 
protein MD-2. The TLR4 signal induced by PA results in the activation and maturation of 
DCs accompanied with a robust IL-1β response. These data suggest DCs recognize PA 
through PAMP associated mechanisms. Thus, PA may serve as a dietary immune 
modifier (DIM) resulting in the induction of chronic inflammation.  
 
Materials and Methods 
 
Monocyte Isolation and DC Culture 
 Human monocyte-derived DCs were generated as previously described 
(Kiertscher and Roth 1996).  Peripheral blood from healthy adult donors (age 18+) was 
provided by the Lifestream blood bank, San Bernardino, CA, according to Loma Linda 
University IRB requirements. After red blood cell lysis, CD14+ cells were isolated with 
anti-CD14 magnetic bead MACS separation (Miltenyi biotech) and cultured for 6 days in 
RPMI 1640 medium +10% FBS with GM-CSF and IL-4.  
 
Preparation of PA 
 Palmitic acid (Sigma, St. Louis, MI), was dissolved in 100% EtOH and diluted 
(final conc. EtOH 0.1% v/v) in a range from 300 to 50 μM in a 2:1 molar ratio with 
endotoxin low FA-free BSA (Gemini Bio-products) in media containing defatted-FBS 
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(no experimental differences were observed between using FBS and defatted-FBS). DCs 
treated with physiological doses of PA (300μM, 150μM, and 50μM) were viable within 
48hrs of treatment (data not shown).  
 
Reagents 
 The ROS scavenger, MCI-186 (Biomol Research Laboratories) was dissolved in 
DMSO and diluted in a range from 1mM or 50μM. DCs were pre-treated with MCI-186 
for 1hr. The TLR4 inhibitor CLI-095 (Invivogen) was used according to manufacturer 
protocol. The caspase-1 inhibitor peptide (ICE Inhibitor V, Z-Asp-[(2,6-
dichlorobenzoyl)oxy]methane, Z-D-CH2-DCB from Calbiochem) was used at a 
concentration of 100μM. Vehicle control contained equimolar amounts of BSA, EtOH, or 
DMSO as used in experimental groups.  
 
Antibodies and Flow Cytometry 
Abs and reagents used were anti-human CD11c-PE, CD80-FITC, CD80-PE, 
CD83-FITC, HLA-DR-PerCP, CD11c-PE-Cy7, CD83-APC, CD86-PE, CD282-FITC, 
CD284-PE, Donkey anti-rabbit-FITC, fixable viability dye e-flour 450, and Anti-human 
CD14-PE,-APC, or -VB (Biolegend, BD biosciences, or Miltenyi Biotech). Data 
acquisition was on a Miltenyi MACSQuant flow cytometer (Miltenyi Biotech) and 
analysis was performed with FlowJo 7.6.5 (Tree Star, Ashland, OR) software. 
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Figure 13. Basic DC Gating Strategy. (A) DCs were gated first by FSC-A and SSC-A. 
Doublet discrimination was performed using FSC-H vs FSC-W and SSC-H vs SSC-W. 
Cells with the phenotype CD11chi were gated as DCs (>94%). (B) DCs express higher 
levels of CD11c than their precursor monocytes. (C) DCs express higher levels of HLA-
DR than their precursor monocytes. (D) Western blot and Coomassie stain of SDS-PAGE 
of isolated rTLR4 and rMD-2 from Hela cells. 
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Flow Cytometry Gating Strategy 
DCs were gated by FSC-A/SSC-A. Doublet discrimination was performed using 
FSC-H vs FSC-W and SSC-H vs SSC-W(Wersto, Chrest et al. 2001). Dendritic cells or 
CD11chi cells (>94%) all expressed increased HLA-DR as compared to monocytes 
(Figure 13A,B, and C).  
 
qRT-PCR 
 Total RNA was isolated from DCs using Stat-60 reagent (Tel-Test Inc.) according 
to the manufacturer’s protocol. After reverse transcription with SydQuanti First Strand 
cDNA Synthesis Kit (SydLabs Inc.), qRT-PCR was performed with iQ SYBR Green 
Super Mix (Bio-rad) on a Bio-rad CFX96 Real-time system C1000tm thermal cycler. 
Values were normalized to β-actin (see Table 2).  
 
Table 2. Primer sequences designed with NCBI primer blast for qRT-PCR 
Primer Product size (bp) Sequence 
IL-12p40 forward 
IL-12p40 reverse 
107 5’- CTTGGACCAGAGCAGTGAGG -3’ 
5’- GAACCTCGCCTCCTTTGTGA -3’ 
IFN-γ forward 
IFN-γ  reverse 
136 5’- TCCAGTTACTGCCGGTTTGA -3’ 
5’- TGGAAGCACCAGGCATGAAA -3’ 
IL-1β  forward 
IL-1β  reverse 
143 5’- TGAGCTCGCCAGTGAAATGA -3’ 
5’- AGATTCGTAGCTGGATGCCG -3’ 
NLRC4  forward 
NLRC4  reverse 
59 5’- TCATCGGTGGAGTGGACCAA -3’ 
5’- TTCTGGGCAAGGTCACACAG -3’ 
 
 
 
Cytometric Bead Array 
Supernatant was collected from DC cultures following PA treatment and analyzed 
with multiplexed human IL-12p40, IFN-γ, IL-6, TNF, and IL-1β flex sets as described by 
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the manufacturer (BD biosciences) on the MACSQuant flow cytometer.  Data analysis 
was accomplished with FACP array v3 software. 
 
Recombinant TLR4/MD-2 
 Recombinant TLR4/MD-2 (Figure 13D) was isolated from stably transfected Hela 
cells according to published protocol (Illana and Farhaeus 2012). A plasmid (vector 
pD1119 cloned by DNA 2.0) encoding the TLR4 ectodomain (Accession # O00206; 
Glu24 - Lys631 + 10-His Tag) and MD-2 (Accession # Q9Y6Y9; Glu17 - Asn160 +10-
His Tag) separated by the sequence for a viral 2A peptide was used to produce lentivirus. 
Transduced Hela cells were expanded in DMEM + 10% FBS and 1μM puromycin 
(Sigma-Aldrich). 
 
Isothermal Titration Calorimetry 
 Isothermal titration calorimetry (ITC) experiments were carried out in a low 
volume Nano ITC (TA instruments). Electrical and chemical calibration was done 
according to manufacturer’s instructions (Demarse, Quinn et al. 2011). 200uL of 13-
30μM recombinant human TLR4/MD2 in ITC buffer (Tris/HCL pH 8, 1mM EtSH, 
900μM KOH) was loaded into the cell. The syringe was loaded with 500-800 μM PA. 
Titrations were carried out using 22 injections of ~2.5μL each at 400s intervals, at 25°C. 
Data was analyzed using NanoAnalyze v2.4.1 software (TA Instruments). Data was fitted 
using an independent binding model. 
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Fluorescence Microscopy 
 Dendritic cells were cultured on glass slides. After 20min treatment with PA or 
PA+CLI-095, the cells were fixed and stained with primary anti-human phospho 
NFκBp65 (Cell Signaling Technologies) and secondary donkey anti-rabbit FITC 
(Biolegend). Slides were sealed after addition of mounting media with DAPI and 40x 
photos were taken on a Keyence BZ-9000 fluorescent microscope. 
 
Electrophoretic Mobility Shift Assay 
 Nuclear lysates of PA treated DCs were incubated with a 32P labeled DNA 
consensus sequence for NF-κB for 30min.  The protein was subjected to gel 
electrophoresis. The gels were dried and exposed on X-ray film.  The band density 
correlates to the relative amount of labeled oligonucleotide bound to NF-κB. 
 
Western Blots 
 Western blots were performed on 50μg of total protein lysate from DCs treated 
with PA or PA+CLI-095 for reported time points to detect caspase-1 (anti-caspase-1 Cell 
Signaling Technologies). 
 
Statistical Analysis 
 One or two way-ANOVA was performed with GraphPad Prism 6.00 software 
(GraphPad, San Diego, CA), and values at P <0.05 were deemed significant (**=p<0.01, 
***=p<0.001, ****=p<0.0001).   
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Results and Discussion 
PA Binds and Induces Internalization of TLR4 
 To date, no one has demonstrated that PA acts as a TLR4 ligand. The crystal 
structure of the TLR4 ectodomain, MD-2, and LPS show that five hydrophobic carbon 
chains of the lipid A portion of LPS bind MD-2 (Park, Song et al. 2009).  Because PA 
has structural similarity to the carbon chains of lipid A, up to five molecules of PA may 
potentially bind the hydrophobic pocket of MD-2. Our results show that PA binds to 
TLR4/MD-2 with an affinity (Ka) of 4.355x105 (Figure 14A). The PA binding to TLR4 is 
endothermic, exergonic, and spontaneous as evidenced by a positive ∆H, large positive 
∆S, and negative ∆G respectively (Figure 14A). We validated the interaction of PA and 
TLR4/MD-2 by assessing DC internalization of TLR4 in response to PA. We found that 
PA significantly reduced surface TLR4 but not as much as LPS (Figure 14B). Of note, 
the kinetics of PA-induced TLR4 endocytosis is linear while LPS-induced TLR4 
endocytosis is initially exponential.  
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Figure 14. PA binds TLR4. (A) Isothermal titration calorimetry. Isotherms and fitted area 
curve of PA into TLR4/MD-2 titration. Bottom panel insert contains thermodynamic 
parameters for PA and TLR4/MD-2 binding interaction. (B) PA induces the internalization 
of TLR4. DCs were treated with 300μM PA for indicated time intervals. Cells were stained 
for flow cytometry. CD14-CD11chiHLA-DRhi cells were assessed for TLR4. Data is 
presented as the percentage of baseline Geometric MFI. Graphs display the mean ± SEM. 
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The high affinity of PA for TLR4/MD-2 indicates how an increase in dietary PA 
may stimulate innate immune cells. PA’s association with TLR4/MD-2 is an order of 
magnitude weaker than that of LPS interaction with MD-2 (Kd ~ 3nM) (Akashi, Saitoh et 
al. 2003). However, the Ka of PA binding to TLR4/MD-2 is greater than that of PA 
binding to any of the three low affinity human serum albumin binding sites (Fujiwara and 
Amisaki 2008). Under normal conditions, the low affinity binding sites are not occupied. 
However, these sites are occupied under conditions of increased lipolysis and serum FAs. 
Therefore, both serum PA and PA bound to low affinity sites could potentially bind 
TLR4/MD-2 in vivo.  
 
PA Induces DC Maturation and Secretion of IL-1β 
 To determine if PA activates DCs through upregulation of co-stimulatory factors, 
naïve DCs were treated with PA and assessed for the expression of HLA-DR, CD80, 
CD86, and CD83 surface markers by flow cytometry (Figure 15A). PA induced the 
expression of CD86 as well as the maturation marker, CD83, indicating simultaneous 
induction of DC activation and maturation. We also examined the effects of PA on DC 
production of inflammatory cytokines IL-6, TNF, IFN-γ, IL-12, and IL-1β using qRT-
PCR and cytometric bead array for secreted cytokines.  PA seemed to increase IFN-γ 
secretion although this trend was not significant. There was no effect on IL-12 production 
and, PA also failed to increase the secretion of IL-6, TNF-α, IL-8 or IL-10, but increased 
IL-18 mRNA (data not shown). In contrast, PA induced robust mRNA expression of pro-
IL-1β and the secretion of active IL-1β (Figure 15B and C).  
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Figure 15. PA induces DC maturation and secretion of IL-1β. (A) PA upregulates 
DC activation and maturation markers. DCs were treated with 150μM PA for 12hrs. 
Representative histograms from 1 of 8 individual patient samples is presented, and the 
geometric MFI for the indicated marker on CD11chi cells (DCs) is graphed. (B) mRNA 
fold change in cytokines of DCs treated with 300μM PA. (C) Quantification of cytokines 
secreted from DCs treated with 300μM PA. ND = Not detectable. 
 
 
Palmtic Acid Activation of NF-κB is TLR4 and ROS Dependent 
TLR4 signaling results in the activation of NF-κB, an event required for transcription of 
pro-IL-1β. We determined that PA induces the activation (phosphorylation) of NF-κBp65 
(Figure 16A-C and Figure 17A). This activation is inhibited by blocking TLR4 with CLI-
095 (Figure 16A-B) and ROS with MCI-186 (Figure 16C). Next, we determined that 
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CLI-095 completely eliminated the IL-1β response to PA, but was not affected by MCI-
186 (Figure 16D). Therefore, both PA ligation of TLR4 and ROS generation may be 
necessary for PA to exert its maximum effects.  
 
 
Figure 16. PA activation of NF-κB is TLR4 and ROS dependent. (A-B) PA-induced 
phosphorylation of NF-κBp65 is TLR4 dependent. DCs were treated with 300μM PA for 
20min and analyzed for phospho NF-κBp65 (green) by fluorescence microscopy. (B) 
Quantitation of MFI phospho NF-κBp65 relative to DAPI (blue). (C) PA-induced 
activation of NF-κB is ROS dependent. DCs were treated with 300μM PA for 3hrs and 
analyzed by EMSA. (D) DC secretion of IL-1β is dependent on TLR4 signaling. DCs were 
treated with 150μM PA for 36hrs +/- CLI-095 or 50μM MCI-186. The supernatant was 
analyzed for concentration of IL-1β. Figure is representative of at least 3 separate patient 
samples.   
 
 
Secretion of IL-1β is Dependent on TLR4 Induced Caspase-1 Activation 
 Although caspase-1 typically processes pro-IL-1β, caspase-8 which is also 
induced by TLR4, has the ability to cleave pro-IL-1β (Maelfait, Vercammen et al. 2008). 
To determine if PA-induced secretion of pro-IL-1β in DCs relies on caspase-1, we 
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assessed the secretion of IL-1β in the presence of a specific caspase-1 inhibitor. The 
inhibition of caspase-1 knocked out almost 100% of IL-1β secretion (Figure 18B). 
 Since caspase-1 activity is essential for IL-1β secretion, we assessed the ability of 
PA to induce activation of caspase-1 in DCs. We found that PA minimally increased the 
production of active p20 caspase-1 within 2 hours with a maximum at ~30min, while 
CLI-095, a TLR4 inhibitor, repressed this process (Figure 18C and 17B), indicating that 
activation of caspase-1 may be dependent on TRIF/TRAM TLR4 signaling or direct 
interaction with PA rather than ROS (Legrand-Poels, Esser et al. 2014).  
 
PA Induces NLRC4 Inflammasome Transcription 
Non-esterified FAs seem to have the ability to directly stimulate inflammasome 
activation (Reynolds, McGillicuddy et al. 2012, Legrand-Poels, Esser et al. 2014). PA 
increased NLRC4 mRNA approximately 10-fold (Figure 18A) without affecting NALP1 
or NALP3 mRNA (data not shown). This result suggests it is likely that PA-induced 
caspase-1 activation is via the NLRC4 inflammasome (Figure 19). Both ex vivo and in 
vivo exposure of bone marrow-derived DCs to dietary saturated FAs increased NLRP3 
inflammasome activation (Reynolds, McGillicuddy et al. 2012). Our studies indicate that 
the NLRC4 inflammasome, rather than NLRP3, is active in processing pro- IL-1β. 
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Figure 17. (A) Representative microscopy of DCs treated with PA for 20min. Green 
represents the presence of phospho NF-κBp65 and blue represents DAPI staining of nuclei. 
(B) Densitometry quantification of western blots of active caspase p20 from Figure 18C. 
Data was analyzed using one-way ANOVA. * = p < 0.05. 
 
 
This difference may be due to our use of PA as opposed to a mixture of saturated 
FAs. However, Luo et al. demonstrated that PA specifically activates NLRC4 in HepG2 
cells (Luo, Yang et al. 2012). For the first time, we show that PA initiates innate 
immunity in DCs by binding TLR4 and inducing IL-1β secretion. Overall, our studies 
suggest that dietary PA is a key metabolic stressor required for the processing of IL-1β in 
DCs. Understanding the mechanism of PA as a dietary immune modulator (DIM) 
underscores the importance of researching lipid effects on immune cells. The emergence 
of mechanistic data on DIMs such as FAs has the potential to provide novel molecular 
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targets for therapy in a host of inflammatory diseases including hypersensitivity 
dermatitis, rheumatoid arthritis, and type 2 diabetes. 
 
 
 
Figure 18. PA activates inflammasomes. (A) PA induces NLRC4 gene expression. DCs 
were incubated with 300μM PA for 6hrs and NLRC4 mRNA was analyzed by qRT-PCR. 
(B) PA secretion of IL-1β is caspase-1 dependent. The supernatant from DCs treated with 
300μM PA for 24hrs was analyzed by cytometric bead array. (C) PA-induced caspase-1 
activation is TLR4 dependent. DCs were treated with 300μM PA for increasing time points. 
The DC lysates were analyzed by western blot. Data is representative of 3 experiments and 
normalized to β-actin. 
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Figure 19. Mechanism of PA-induced DC secretion of IL-1β. (1) PA binds MD-2/TLR4 
and induces signal transduction resulting in NF-κB activation. (2) NF-κB induces 
transcription of the pro-IL-1β gene which results in translation and protein expression. (3-
4) PA-induced TLR4 signal transduction also results in activation of caspase-1, a process 
which occurs via inflammasome assembly. (5) Caspase-1 cleaves pro-IL-1β into active IL-
1β. (6) With the secretory peptide signal exposed after cleavage, IL-1β is secreted from the 
cell.  
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CHAPTER FOUR 
POTENTIAL MOLECULAR MECHANISMS FOR PA ACTIVATION OF 
DENDRITIC CELLS  
Abstract 
Palmitic Acid has the ability to activate dendritic cells by binding toll-like 
receptor 4 (TLR4). However, the mechanisms underlying PA manipulation of DC 
activation remains unclear. In this chapter, we investigate potential mechanisms by which 
PA stimulates DC function.  To achieve this goal, we employed both a focused and a 
broad approach. Specifically, we used the reactive oxygen species (ROS) scavenger 
MCI-186 and the NADPH oxidase inhibitor Apocynin to elucidate the role of ROS in PA 
mediated DC activation. Broadly, we also analyzed all changes in the DC proteome in 
response to PA treatment by mass spectrometry. We found that ROS is involved in the 
DC response to PA ligation of TLR4. In addition, our data suggests that PA treated DCs 
may have the ability to stimulate an adaptive T cell response. In conclusion, we found 
that ROS plays a role in PA induced DC activation, and the role of PA activated DCs on 
the adaptive immune system should be researched further. Determining whether PA can 
stimulate an adaptive immune response will shed light on how increased serum fatty 
acids may induce insulin resistance and subsequent type 2 diabetes. 
 
Introduction 
 Dietary fatty acids (FAs) play a major role in diabetes inflammation (Pickup and 
Crook 1998, Halliwell 2002, Unger and Parkin 2010). Saturated FAs, e.g. palmitic acid 
(PA), are pro-inflammatory and have been associated with metabolic syndrome, insulin 
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resistance, and various immunological complications leading to type 2 diabetes (Kim, 
Pham et al. 2007, Riserus 2008, Titov, Krylin et al. 2011). In diabetes patients, serum 
saturated FAs are correlated with inflammation (Riserus 2008, Unger and Parkin 2010, 
Virtanen, Niinisto et al. 2010). The impact of saturated FA on the immune system can be 
attributed in part to their interaction with dendritic cells (DCs), the primary antigen 
presenting cells responsible for activating naïve T cells. While many laboratories have 
shown the pro-inflammatory effects of PA on DC function (Zeyda, Saemann et al. 2005, 
Wang, Hao et al. 2007, Igoillo-Esteve, Marselli et al. 2010, Kong, Yen et al. 2010, Piro, 
Maniscalchi et al. 2010), the molecular mechanisms by which PA impacts DCs remain 
largely unknown. 
DCs are professional antigen presenting cells that function by recognizing 
antigens and presenting them to T lymphocytes.  DCs reside in peripheral tissues until 
they encounter antigens that activate them. Activation through TLR signaling pathways 
results in DCs maturation into efficient antigen presenting cells (APCs) (Bell, Young et 
al. 1999). Antigen laden DCs migrate to peripheral lymph nodes, where they interact with 
naïve T cells to promote immune responses (Bell, Young et al. 1999). In vitro, DCs can 
be differentiated  from CD14+ monocytes by incubation in medium containing the 
cytokines GM-CSF and IL-4 (Romani, Gruner et al. 1994). The resulting immature DCs 
are CD14lo, express MHC class II, CD1, and co-stimulatory ligands for T cell surface 
receptors such as B7.1 (CD80) and B7.2 (CD86), in addition to endocytic receptors such 
as DC-Sign and mannose receptor (MR) (Porcelli, Brenner et al. 1989, Romani, Reider et 
al. 1996). In addition to engagement of the T cell receptor and CD28 by dendritic cell 
MHC class II/CD1 and B7 proteins respectively, T cells also require cytokine signaling to 
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become active. Our laboratory has shown that PA binds TLR4 on DCs and induces 
secretion of the pro-inflammatory cytokine IL-1β. The aim of this study is to identify 
mechanisms underlying palmitic acid modulation of DC immune responses.  
We hypothesized that PA induced reactive oxygen species (ROS), specifically 
H2O2, acts as a TLR4 signaling regulator (Finkel 1999, Lee, Sohn et al. 2001, Reth 2002). 
Different from other ROS agents that have indiscriminate chemical reactivity, H2O2 has 
specific biological targets such as proteins with an oxidizable cysteine located in an 
enzyme active site (Finkel 1999, Reth 2002, D'Autreaux and Toledano 2007). Protein 
tyrosine phosphatases are examples of enzymes susceptible to H2O2 regulation. In vitro, 
protein tyrosine phosphatase 1B (PTP1B) activity is reversibly inhibited by H2O2. 
(Salsman, Hensley et al. 2005). Therefore, H2O2 may be necessary for TLR4 signaling 
through inactivation of PTP1B, which negatively regulates TLR signaling (Xu, An et al. 
2008). An emerging hypothesis is that antigen receptor signaling not only requires kinase 
activation but, more importantly, requires the inhibition of tyrosine phosphatases by H2O2 
(Reth 2002).  
 We also propose that PA treated DCs stimulate pro-inflammatory T cell responses 
via lipid antigen presentation of PA on CD1 molecules (Schiefner and Wilson 2009). 
Proteins and lipoproteins are normally presented on dendritic cell MHCI and MHCII 
receptors, but this form of antigen presentation is not possible for lipids. Lipids are 
presented on a family of MHC-like proteins called CD1 molecules that are divided into 
two groups: group 1 (CD1a,b,and c) and group 2 (CD1d). Group 1 CD1 molecules have 
been shown to present foreign lipid antigens from mycobacteria to CD1 restricted T cells. 
Group 2 antigens are presented on CD1d to NKT cells (Cohen, Garg et al. 2009).  In this 
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chapter, we show that PA induces ROS in DCs which may regulate PA activated TLR4 
signaling. We also demonstrate that CD1b may play a role in the adaptive immune 
functions of PA activated DCs. 
 
Materials and Methods 
Monocyte Isolation and DC Culture 
 Human monocyte-derived DCs were generated as previously described 
(Kiertscher and Roth 1996, Mbongue, Nicholas et al. 2015).  Peripheral blood from 
healthy adult donors (age 18+) was provided by the Lifestream blood bank, San 
Bernardino, CA, according to Loma Linda University IRB requirements. After red blood 
cell lysis, CD14+ cells were isolated with anti-CD14 magnetic bead MACS separation 
(Miltenyi biotech) and cultured for 6 days in RPMI 1640 medium +10% FBS with GM-
CSF and IL-4.  
 
Preparation of PA 
 PA (Sigma, St. Louis, MI), was dissolved in 100% EtOH and diluted in a range 
from 300 to 50 μM in a 2:1 molar ratio with endotoxin low FA-free BSA (Gemini Bio-
products) in media with defatted-FBS (EtOH 0.1% v/v).   
 
PCR 
 Total RNA was isolated from DCs using Stat-60 (Tel-Test Inc.) according to the 
manufacturer’s protocol. After reverse transcription with SydQuanti First Strand cDNA 
Synthesis Kit (SydLabs Inc.), RT-PCR was performed with Amplitag Gold Fast PCR 
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Master Mix (Applied BioSystems) on an Eppendorf Mastercyler thermal cycler. 
Densitometry was performed and values were normalized to β-actin. Primers for IL-1β, 
IL-12/23p40, and IFN-α were designed using NCBI primer blast. 
 
Cytometric Bead Array 
Supernatant was collected from DC cultures following 24 hours of 150μM PA 
treatment and analyzed with multiplexed human IL-1β, IL-12/23p40, and IFN-α flex sets 
as described by the manufacturer (BD biosciences) on MACSQuant flow cytometer.  
Data analysis was accomplished with FACP array v3 software. 
 
 
Antibodies and Flow Cytometry 
Antibodies and reagents used were anti-human CD86-FITC, CD80-PE (BD 
Pharmingen), CD11c PE, HLA-DR PerCP (Becton Dickinson), CD14-APC (Biolegend), 
Annexin V FITC (ebioscience), Propidium Iodide (PI) (BD Pharmingen), 7 
aminoactinomycin D (7AAD) (Biolegend). Data acquisition was on a Miltenyi 
MACSQuant flow cytometer (Miltenyi Biotec) and analysis was performed with FlowJo 
7.6.5 (Tree Star, Ashland, OR) software. 
 
Flow Cytometry Gating Strategy 
DCs were gated by FSC-A/SSC-A. Doublet discrimination was performed using 
FSC-H vs FSC-W and SSC-H vs SSC-W. Cells with the phenotype HLA-DRhiCD11chi 
were gated as DCs (>94%). 
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Caspase 3/7 Activity Assay 
 To assess caspase 3/7 activity, monocytes were seeded at 2x105 in a white flat 
bottom 96-well plate. After DC differentiation and FA treatment, the cells were incubated 
with 50µL of  3× caspase buffer [150mM Hepes pH 7.4, 450mM sodium chloride, 
150mM potassium chloride, 30mM magnesium chloride, 1.2mM ethylene glycol-bis (2-
aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA), 30% sucrose, 10% CHAPS, and 
1.5% NP-40] and fluorogenic peptide caspase 3/7 substrate Ac-DEVD-AMC as 
recommended by manufacturer (Fisher Scientific) for 2 h at room temperature in the 
dark. Half of the samples were also incubated with DVED-CHO (Fisher Scientific), a 
caspase 3 specific inhibitor, to ensure the efficacy of the assay. Absorbance was then read 
in a MicroLumat Plus LB 96v Fluorescent Reader (EG&G Berthold) at excitation of 360 
nm and emission of 460 nm. 
 
Measurement of DC Intracellular Reactive Oxygen Species (ROS) 
 To measure ROS, dendritic cells, both PA treated and untreated, were incubated 
with 25 µM 2’,7’-dichlorofluorescein diacetate (H2DCF-DA) (Invitrogen) for 20 min at 
37°C. The negative control sample was treated with 1mM MCI-186 (Biomol Research 
Laboratories, Plymouth Meeting) dissolved in DMSO for 24 hrs. The positive control 
samples were incubated with 10 µM H202 for 10min prior to the addition of H2DCF-DA. 
The H2DCF-DA readily diffuses into the cells where it is hydrolyzed to the polar non-
fluorescent molecule 2’,7’-dichlorofluorescein (H2DCF). The DCFH is readily oxidized 
by ROS into the fluorescent molecule 2’,7’-dichlorofluorescein (DCF) within the cell 
(Hempel, Buettner et al. 1999). Following dye treatment, the DCs were harvested by 
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washing the cells from the wall with DPBS and then centrifuged (at 4°C at 24 x g for 5 
min). Supernatant was aspirated and samples were resuspended in 200µL DPBS and 
analyzed via flow cytometry. Excitation/emission wavelengths for fluorescence 
measurements of the samples were 488 nm and 530 nm respectively. 
 
Measurement of DC H2O2 with PF6-AM 
 Dendritic cells were cultured in 3cm2 plates. The DCs were then incubated in PBS 
with 5μM PF6-AM for 30min at 37°C (Basu, Rajakaruna et al. 2014). The SPOT 
ADVANCED software was used to set the microscope settings: 10x magnification, 
exposure time = 300msec, binning= none, brightness =1, gain =1, and measure full chip, 
multiple photos setting with exposure time on manual. The DCs incubated with the PF6-
AM were then placed on a Zeiss fluorescent microscope. PBS with excess PF6-AM 
removed and a baseline photo of fluorescence was taken. SPOT ADVANCED was setup 
to take a photo every 0.5s for 30 min. Media containing treatments was added and photos 
were initiated simultaneously. Fluorescence was quantified using Image J and normalized 
to baseline fluorescence. Excitation/emission wavelengths for PF6 were 488 nm and 520 
nm respectively. 
 
Microscopy 
 Dendritic Cells were plated on 8-well chamber slides. After 24 hour treatment 
with 150uM BODIPY FL C-16 (Life Technologies) complexed 2:1 with BSA, the DCs 
were stained for microscopy as previously described (Zhu 2012). Antibodies used were 
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anti- human CD74, CD1a, CD1b, CD1c, and anti-mouse IgG1-APC (eBioscience). DCs 
were imaged on a Zeiss LSM 710 NLO at 40x magnification. 
 
PA Treated DC Sample Preparation and Mass Spectrometry Analysis 
After 24 hr treatment with 150 μM PA complexed 2:1 with BSA, the DCs were lysed on 
ice for 2 hours in radio-immunoprecipitation assay (RIPA) buffer ( Santa Cruz 
Biotechnology, CA) containing 1% Nonidet P40, PMSF (0.2 mM), and protease inhibitor 
cocktail (Roche). The protein mixture was centrifuged at 10,000 rpm at 4°C for 15 
minutes in a Beckman GS-15R centrifuge equipped with a F2402 rotor and the 
supernatant transferred into a clean tube. The protein concentration in the supernatant 
was determined by BCA Protein Assay (Thermo Scientific Pierce, Rockford, IL USA). 
Approximately 60 μg of each protein sample was resuspended in 25mM 
triethylammonium bicarbonate buffer, pH 7.8. The protein was reduced with a final 
concentration of 10 mM DTT and incubated at 50°C for 30 minutes, followed by 
carboxymethylation achieved by addition of 25 mM iodoacetamide (final concentration) 
and incubation of the mixture in the dark for 1 hour. The proteins were precipitated by 
addition of 4 volumes of precooled (-20°C) acetone and stored at -20°C overnight. The 
protein was pelleted at 14,000 rpm in the Beckman GS-15R centrifuge for 10 minutes at 
4°C and the supernatant discarded. The protein pellet was dissolved in 25 mM 
triethylammonium bicarbonate buffer (100 μM GTP, 100 μM GDP in 8 mM PIPES pH 
6.8) and partially digested by trypsin (Sigma-Aldrich, St. Louis, MO) at a protein / 
trypsin enzyme ratio of 25:1 (by mass) for 10 hours at 37°C. 
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 A Tandem Mass Tagging isobaric (TMT) Kit (Thermo-Fisher Scientific) was 
used to label the peptides following the manufacturer’s recommended conditions. Each 
TMT-labeled protein pool was acidified with 0.1% Formic Acid (FA) and fractionated by 
strong cation-exchange (SCX) chromatography on a Toptip column (Poly LC, MD). For 
fractionation, the column matrix was equilibrated with 0.1% FA in 20% acetonitrile 
(ACN) to facilitate peptide binding. After collection of the flow-through volume, 1.0 mL 
of each sub-fraction was eluted sequentially with 20% ACN, 0.05 M KCl, 0.2 M KCl, 0.5 
M KCL, and 5% ammonium hydroxide in 20% ACN. Next, the fractions were dried 
under vacuum to remove the ACN, reconstituted in 1% formic acid, and desalted using a 
Toptip column with C18/hypercarb mixed materials (Poly LC, MD). The eluted peptides 
were once again vacuum-dried, reconstituted in 30 μl of 0.1% FA, and subjected to LC-
MS/MS analysis. The peptides were separated by online reversed phase liquid 
chromatography (RPLC) using an Easy-nLC equipped with an auto-sampler (Thermo 
Scientific). A 10 cm, 75 μm id, 3-μm particle size, C18-A2 analytical column (Thermo 
Scientific) was used for the RPLC separations. Quantitation of the SCX fractionated 
TMT-6 labeled peptides was carried out on the Thermo LTQ-Orbitrap Velos Pro mass 
spectrometer. Approximately 2 μg of peptide sample was injected in the analytical 
column. A pre-column (Thermo, 0.1 × 2 cm, 5 μm C18-A1) was brought in line with the 
analytical column and a 250-min gradient (solvent A, 0.1% FA in water; solvent B, 0.1% 
FA in ACN) from 5–30% solvent B was used for separating the peptides. The Orbitrap 
mass analyzer was set to acquire data at R = 60,000 resolution for the parent full-scan 
mass spectrum, followed by data-dependent high collision-energy dissociation (HCD) 
MS/MS spectra for the top 12 most abundant ions acquired at R = 7500 resolution. 
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DC Proteome Data Analysis 
 PA treated DC proteins were identified and quantified by analysis with the 
Proteome Discoverer 1.4 platform (Thermo) and the Mascot search engine (Mascot 
Darmon 2.2.2; Matrix Science, London, UK) employing the International Protein Index 
(IPI) Homo sapiens database (version 3.73, June 2010, containing 89739 entries). Mascot 
searching parameters were used as follows: Carbamidomethylation of cysteine and TMT-
6 modification of the peptide N-terminus and lysine were set as fixed modifications and 
oxidation of methionine and deamination of asparagine and glutamine were set as 
variable modifications. Trypsin was the protease selected and preparations containing up 
to two missed cleavages were used. Mass tolerance for the precursor ions was 10 ppm 
and for the MS/MS 0.2 Da. The peptides were filtered for a maximum false discovery 
rate of 1%. At least one unique peptide with a posterior error probability of less than 0.05 
was accepted for quantification using the grouped TMT-reporter ions and proteins. 
 
Ingenuity Pathway Analysis of the PA Treated DC Proteome 
 The Ingenuity Pathway Analysis program (IPA, Ingenuity Systems, 
www.ingenuity.com) (Qiagen, USA) is an intuitive web-based application for rapid and 
accurate analysis and interpretation of the biological meaning in genomic and proteomic 
data. Analysis of pathways were made using log2 fold-changes and p-values between 
two-group comparisons. The ratios of significant protein expression levels were 
determined at r = 1.25. Multivariate statistics analysis using the “R” program has 
previously been utilized for metabolic profiling (Reitman, Jin et al. 2011).  We have 
adapted this method for protein expression statistics analysis. Multivariate statistics and 
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associated graphics were performed in R, version 64.25.1. Heat maps were drawn using 
the heatmap.2 function found in the g-plots package. 
 
Statistical Analysis 
One or two way-ANOVA was performed with GraphPad Prism 6.00 software (GraphPad, 
San Diego, CA), and values at P <0.05 were deemed significant (**=p<0.01, 
***=p<0.001, ****=p<0.0001).   
 
Results 
Palmitic Acid Induces Dendritic Cell Secretion of Pro-inflammatory Cytokines 
 Our lab previously demonstrated that PA matures and activates DCs as measured 
by upregulation of CD86 and CD80 surface expression. In addition, we have also shown 
that PA binds TLR4 and induces signaling that results in secretion of IL-1β. Preliminary 
data from our laboratory indicated that other TLR4 dependent pro-inflammatory 
cytokines may also be released from DCs upon exposure to PA. We therefore evaluated 
the cytokine profile of PA treated DCs. We first incubated DCs with 300μM PA for 
either 3 or 6 hours. Following the incubation, we isolated mRNA from the cells and 
performed RT-PCR to identify the presence of mRNA of the following inflammatory and 
anti-inflammatory cytokines or their subunits: IL-8, IL-10, IFN-γ, IL-12/23p40, IFN-γ, 
IFN-α, IL-6, and IL-1β. We also cultured DCs with PA for 24hrs and assessed the 
supernatant for secreted cytokines using cytometric bead array. Our results confirmed our 
previous finding that IL-1β is induced by PA treatment (Figure 20A, D, H, and K). 
Additionally, we found that both IL-12/23p40 and IFN-α are secreted by DCs in response 
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to PA (Figure 20I and J). The p40 cytokine subunit detected is assumed to be from IL-23 
rather than IL-12 due to failure to detect active IL-12p70 (Figure 15) and will be referred 
to as IL-23 for the remainder of this chapter. 
 
 
Figure 20. Palmitic acid upregulates dendritic cell pro-inflammatory cytokines. Immature 
DCs were treated with 300μM PA complexed 2:1 with BSA for 3 or 6 hrs. After palmitic 
acid incubation, mRNA was isolated from the cells and reverse transcribed into cDNA. 
Semi quantitative RT-PCR was performed for the cytokines indicated above. (A) 
acrylamide gel images of RT-PCR results after 3 hours of PA treatment. (B,C, and D) Bar 
graph representation of semi-quantitative analysis of PCR gel from (A). (E) acrylamide gel 
images of RT-PCR results after 3 hours of PA treatment. (F,G, and H) Bar graph 
representation of semi-quantitative analysis of PCR gel from (E). The DCs were incubated 
with 150μM palmitic acid for 24 hrs (I,J, and K). The cell supernatants were collected and 
analyzed for the levels of the indicated cytokines after PA and PA + ROS inhibitors MCI-
186 and Apocynin treatment by cytometric bead array. Statistical analysis of the data was 
performed using One way ANOVA (*=p<0.05, **=p<0.01).  
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Palmitic Acid Induces Dendritic Cell Death 
 Apoptosis in macrophages was shown to be TLR4 dependent (Haase, Kirschning 
et al. 2003). Because PA was identified as a TLR4 ligand and has been documented to 
cause lipotoxicity, we assessed its effects on DC viability. To determine DC viability, a 
modified Annexin V and PI assay for apoptosis was used (Figure 21A-C). We measured 
the viability of DCs treated with physiological doses (high = 300uM, medium = 150uM, 
and low = 75uM, representing PA serum levels in a fasting autoimmune patient or type 2 
diabetic, in a fed-state autoimmune patient, and in a normal individual, respectively 
(Fraser, Thoen et al. 1999)) of PA  and found that all concentrations of PA caused 
significant cell death at 48 hours.  However, none of these doses induced significant cell 
death at time points up to 24 hrs. Thus, all doses up to 24 hours can be used for functional 
assays. Additionally, we found that PA induced DC death was accompanied by activation 
of caspase 3/7 (Figure 21D). 
 ROS has been demonstrated to be important in TLR4 signaling (Maloney, Sweet 
et al. 2009). Moreover, it is well documented that addition of PA to cells results in 
increased ROS (Maloney, Sweet et al. 2009). To characterize the role PA generated ROS 
plays in TLR4 dependent apoptosis in DCs, we co-treated DCs with PA and MCI-186, a 
non-specific ROS scavenger. We found that blocking ROS completely inhibited caspase 
3/7 activity, indicating a role for ROS in PA-induced cell death (Figure 21D). However, 
blocking ROS with MCI-186 could not rescue DCs from PA-induced cell death. Thus, 
ROS may have other roles to play in DC function. We found that blocking ROS with 
MCI-186 or with Apocynin (an inhibitor of NADPH oxidase activity) inhibits IL-23p40 
secretion and amplifies IL-1β secretion (Figure 20I, J, and K). To assess whether ROS is 
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involved in regulating DC activation, we co-treated DCs with PA and MCI-186 and 
measured co-stimulatory factor expression. We found that blocking ROS resulted in the 
inhibition of PA-upregulated CD86 and CD80 (Figure 22). These results implicate ROS 
in PA mediated DC activation. In addition, we previously showed PA-induced NF-κB 
activation through TLR4 is dependent on ROS. Together, this data led us to further 
investigate the role of ROS in PA-mediated DC activation.  
 
Palmitic Acid Induces ROS in Dendritic Cells 
 To confirm PA generation of ROS in DCs, we first directly measured ROS in PA 
treated DCs. As expected, PA increased the levels of ROS after 24 hrs of treatment 
(Figure 23A). Ingenuity pathway analysis of proteome changes induced by PA in DCs 
after 24 hrs supported this finding (Figure 23B, C and D). Because PA stimulates TLR4 
and TLR4 has been shown to activate NOX4 (Park, Jung et al. 2004), we were also 
interested in PA generated H2O2 oxidative bursts that may contribute to regulation of 
TLR4 signaling in dendritic cells (Asehnoune, Strassheim et al. 2004).   
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Figure 21. Dendritic cell viability following high (300μM), medium (150μM) and, low 
(75μM) dose PA treatment. Monocyte-derived dendritic cells were inoculated with PA in 
a 2:1 molar ratio with BSA for (A) 12 hrs, (B) 24 hrs, or (C) 48 hrs. The cells were analyzed 
for loss of viability by flow cytometry using Annexin V and propidium iodide (PI) staining. 
Lipopolysaccaride (LPS) was used as a control to assess DC activation while MCI-186, a 
free radical scavenger, was used to determine if PA mediated adverse effects were ROS 
dependent. The data is represented as the percent of total DCs negative for both Annexin 
V and PI normalized to the BSA negative control. (D) PA induces caspase 3/7 activity. 
DCs were treated with PA complexed 2:1 with BSA for 36 hrs. Caspase 3/7 activity was 
measured by the emitted fluorescence of cleaved DEVD-AMC. Graphs are representative 
of 3 separate patient samples assayed in duplicate. Statistical analysis was calculated based 
on one way ANOVA (**=p<0.01, ***=p<0.001, ****=p<0.0001). 
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Figure 22. PA induced DC activation is attenuated by MCI-186. Dendritic cells were 
treated with 300μM PA complexed 2:1 with BSA for 36 hrs. Cells were then stained and 
analyzed by flow cytometry. DCs were gated by the phenotype (CD14lowCD11chigh) and 
histograms for the indicated marker was plotted. The shaded histogram is the isotype 
control and the open histogram is the experimental sample. Data is representative of three 
separate experiments.  
 
 
 
H2O2 oxidative bursts would be observed at very early time points. Using fluorescence 
microscopy and the selective H2O2 probe PF6, we showed, similar to LPS the natural 
ligand for TLR4, that PA can induce H2O2 in dendritic cells in seconds (Figure 23E) 
(Basu, Rajakaruna et al. 2014). 
 
Palmitic Acid Impairs Dendritic Cell Antigen Presentation 
 After demonstrating that PA-induced ROS is involved in DC activation, we set 
out to characterize the effects of PA on DC function. We used mass spectrometry to 
measure the levels of proteome changes in PA treated DCs. The significance of these 
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Figure 23. Palmitic Acid induces ROS in dendritic cells. (A) Monocyte derived DCs were treated for 24 hrs 
with PA.  The induction of ROS was determined by measurement of DCF fluorescence and expressed as fold 
increase relative to DCs not incubated with DCF. The addition of the ROS scavenger MCI-186 was included 
as an additional control. The data represents three individual experiments performed in duplicate. (B) 
Comparison of activation z-scores for cellular functions related to ROS production. After 24hr treatment, the 
DC proteome was assessed by mass spectrometry and protein changes were further analyzed using Ingenuity 
Pathway analysis. Transformed z-scores derived from this analysis are displayed on the bar graph. The z-
scores indicate whether the proteome changes in the DC after treatment are associated with the indicated 
cellular functions. (z-score = statistical measurement of a score’s relationship to the mean of a group of 
scores. A z-score of 0 indicates the score is identical to the mean) (C) Network display of the cellular function 
“generation of ROS.” (D) Prediction legend for interpretation of network in panel (C).(E) DCs were pre-
incubated with the specific H2O2 probe PF6-AM. Upon addition of the indicated stimuli, PF6 fluorescence 
was dected by rapid-fire snap shots by the digital camera on a Zeiss fluorescent microscope. The mean 
fluorescence intensity of PF6 was normalized to baseline and plotted against time. 
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protein changes were then further assessed using ingenuity pathway analysis (IPA). The 
IPA program uses an algorithm to determine if a canonical signaling pathway is 
associated with the proteome changes caused by PA a treatment. The significance of 
these associations are indicated by assigned p-values, and with these p-values we 
generated a heat map (Figure 24A).  Based on the proteins detected during mass 
spectrometer analysis, the antigen presentation pathway is the canonical pathway most 
significantly associated with the control DCs (BSA treatment only). PA treatment greatly 
reduced this association. In addition, PA treatment decreased the association of DCs with 
three signaling pathways: “Lipid Antigen Presentation by CD1,” “Leukocyte 
Extravasation Signaling,” and “Communication between Innate and Adaptive Immune 
Cells” (Figure 24A). According to IPA, PA increases “Clathrin-mediated Endocytosis 
Signaling” but not “Calveolar-mediated Endocytosis Signaling.” The influence of PA on 
these signaling pathways was validated by the activation of pathways previously 
associated with PA treatment such as “Mitochondrial Dysfunction” (Padilla, Descorbeth 
et al. 2011), “Fatty Acid Oxidation I,” and “Ketogenesis.” To determine the correlations 
of canonical signaling pathways with PA treatment of DCs, we subjected the p-values 
from the heat map in Figure 24A to principal component analysis (PCA) (Figure 24B). 
The PCA biplot shows that pathway #5 (EIF2 signaling) is the canonical pathway most 
correlated with PA treatment of DCs. EIF2 signaling occurs in response to cellular stress 
and leads to regulation of both global and specific mRNA translation. These results 
suggest that PA is processed by DCs as a stress signal, which as supported by our data, 
results in DC activation and secretion of pro-inflammatory cytokines. 
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Figure 24. Dendritic cell function is downregulated in PA treated DCs. (A) Heat map 
representing canonical pathways [-log(p-values)] identified in PA treated DCs. Increasing 
intensity of red color indicates a higher probability that the indicated pathway is regulated. 
(B) Principal component analysis (PCA) of DC canonical pathways, -log(p-values). The 
Bi-plot correlates dendritic cell regulation of indicated pathways with PA treatment or 
control. These correlations are indicated by the proximity of individual pathways 
(numbers) to either vector arrowhead. Numbers further from the center of the plot in the 
direction of the vector indicates increased correlation of the indicated pathway with the 
designated treatment. Example: Pathway #5 is highly correlated with PA treated DCs, and 
Function #12 is poorly correlated with PA treated DCs. Zero (0) on the x and y axis is the 
weighted mean of the multivariate dataset. The values on the (x; y) axis represent (+/-) 
deviation from the mean of the dataset (0).  
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Palmitic Acid Colocalizes with CD1b and Induces its Downregulation in DCs 
 As previously indicated, DCs require 3 signals in order to direct naïve T cell 
morphogenesis. We have demonstrated that PA affects 2 of these 3 signals: co-
stimulatory factors and cytokines. Our mass spectrometry data indicates that the third 
signal, antigen presentation, is downregulated by PA after 24hrs.  
 This data corroborates earlier findings indicating that saturated fatty acids impair 
protein antigen presentation and that serum lipids and mycobacteria regulate the CD1 
molecules involved in lipid antigen presentation (Leslie, Dascher et al. 2008, Gagliardi, 
Teloni et al. 2009). Although antigen presentation seems to be impaired in PA treated 
DCs, we speculated that lipid antigen presentation via CD1 pathways may still be utilized 
similar to mycolic acid (Cohen, Garg et al. 2009).  Therefore, we assessed changes in 
surface expression of CD1 molecules on DCs in response to PA treatment by flow 
cytometry. We found that CD1b and CD1c were significantly downregulated on the 
surface of DCs in response to PA (Figure 25A). Our mass spectrometry proteome data 
corroborated these findings (Figure 25B) and showed that all proteins identified in the 
CD1 lipid antigen presentation pathway were partially downregulated (Figure 25C). To 
further investigate whether PA could be presented as an autoantigen on CD1 molecules, 
we determined the spatial relationship between PA and CD1 using fluorescence 
microscopy (Figure 25D). Because PA structure is similar to a side chain of mycolic acid, 
a group 1 CD1 antigen, we only assessed the expression of group 1 CD1 molecules on 
DCs in response to PA (Cohen, Garg et al. 2009).  Dendritic cells were incubated with 
150uM BODIPY FL C-16 (a fluorescent PA analog) for 24hrs prior to analysis for 
colocalization with CD1 molecules. The cell images showed a distinct colocalization of  
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Figure 25.  PA treatment affects CD1 expression on DCs. (A) DCs were treated with 
150μM PA complexed 2:1 with BSA for 24hrs. Following incubation, the cells were 
stained for surface receptors and analyzed by flow cytometry. DCs were gated according 
to the phenotype (CD14lowCD11chighHLA-DRhigh) and the normalized MFI for the 
indicated marker was plotted. Statistical analysis was performed using One way ANOVA 
(**=p<0.01, ***=p<0.001). N=3. (B) Mass spectrometry analysis of class I CD1 molecule 
expression in DCs. Compared to monocytes, DCs display increased CD1a and CD1b (red 
circles). Upon 24hr treatment with PA, CD1b is downregulated (green circle). (C) IPA 
output of downregulated molecules in the lipid antigen presentation pathway in PA treated 
DCs. (D) The PA analogue (BODIPY FL C-16) colocalizes with CD1b in DCs. Immature 
DCs were incubated with 150uM BODIPY FL C-16 complexed 2:1 with BSA for 24 hrs. 
Following incubation, the cells were stained with DAPI and CD74 APC, CD1a-APC, or 
CD1b-APC. The cells were imaged at 40x. Colors identifying colocalization: Blue is DAPI 
stain, green is BODIPY FL C-16, red is designated marker, and yellow indicates 
colocalization. The images presented are representative of 4 separate experiments.  
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BODIPY FL C-16 with CD1b, but not with the negative control CD74, or with CD1a and 
CD1c (Figure 25C). The data suggests that PA may be presented as a lipid antigen on 
dendritic cell CD1b. 
 
Discussion 
 In this study, we have identified two potential mechanisms by which PA may 
activate DCs and subsequently induce an inflammatory T cell response. The first 
mechanism is that of ROS production in PA treated DCs. Figure 23 definitively shows 
PA induces ROS, and more specifically H2O2, in dendritic cells. PA activates TLR4 and 
Park et al. demonstrated that TLR4 directly associates with NADPH oxidase 4 (Park, 
Jung et al. 2004). This association results in production of superoxide and downstream 
ROS that is necessary for TLR4 signaling (Maloney, Sweet et al. 2009). Upon blocking 
ROS in DCs with either an ROS scavenger or an NADPH oxidase inhibitor, PA induced 
upregulation of CD86 and secretion of IL-23 is diminished (Figure 20 and 22). Because 
TLR4 signaling requires ROS, reduced secretion of IL-23 is likely due to transcription 
not being initiated. ROS inhibitors had no effect on IFN-α secretion (Figure 20).  
Transcription of IFN-α is regulated by the transcription factors IRF-3 and IRF-7 (Barnes, 
Lubyova et al. 2002). TLR4 activation of IRF-3 and IRF-7 is through TRIF/TRAM 
dependent signaling mechanism which is likely independent of ROS regulation (Palsson-
McDermott and O'Neill 2004, Kawasaki and Kawai 2014). Therefore, blocking ROS in 
PA treated DCs should not affect the transcription and secretion of IFN-α.  
 In the presence of ROS inhibitors, we showed that PA induced IL-1β secretion is 
enhanced (Figure 20). IL-1β secretion is dependent on both TLR4 signaling and active 
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caspase-1 which cleaves pro-IL-1β into active IL-1β. The ROS scavenger MCI-186 
inhibits TLR4 activation of NF-κB, but not completely (Figure 16). Therefore, 
transcription and translation of pro-IL-1β would still occur in the presence of MCI-186. 
We speculate that the ability of ROS scavengers to enhance IL-1β secretion lies in the 
activation of caspase-1. High levels of ROS oxidizes cysteines in the active site of 
caspase-1 and inhibit its activity (Meissner, Molawi et al. 2008). Therefore, reducing 
ROS would allow for maximal caspase-1 activity and enhanced processing of pro-IL-1β 
to active IL-1β. 
 The second mechanism by which PA may activate DCs and subsequently induce 
an inflammatory T cell response is based on CD1b antigen presentation of PA. Dendritic 
cells treated with PA show increased CD86 and CD83 levels (Figure 15) and secrete IL-
1β, IL-23p40, and IFN-α (Figures 15 and 20). This phenotype and cytokine profile is 
consistent with support of pro-inflammatory T cell development. In addition, IL-1β may 
synergize with IL-2 to promote CTL proliferation (Baxevanis, Dedoussis et al. 1994). 
The pro-inflammatory cytokine IL-23 has a role in inducing CTL secretion of IL-17 and 
promotion of diabetes (Ciric, El-behi et al. 2009).    IFN-α was shown to support the 
maintenance of CTLs (Pennock, White et al. 2013). In addition to costimulation and 
cytokine secretion, DCs also need to present antigen in order to activate T cells.  Our 
fluorescence microscopy data shows a pattern of colocalization of the BODIPY analog of 
PA with CD1b. We therefore hypothesize that DCs can present PA to T cells on CD1b 
receptors. However, it is important to first know if PA treated DCs have any pro-
inflammatory effect on T cells before a role for CD1b in this process can be determined.  
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 Understanding how lipids or other components of our diet can affect the immune 
system is key to the treatment of metabolic diseases and especially those diseases 
affected by diet such as type 2 diabetes. Although the area of lipid immunology is still in 
its infancy, it is becoming clear that lipids’ influence on the immune system may be just 
as important as the role protein antigens play. Further research is essential to uncover the 
role fatty acids play in immune regulation. 
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CHAPTER FIVE 
IDENTIFICATION OF ANTI-PALMITIC ACID IGG AUTOANTIBODIES IN 
SERUM OF PATIENTS WITH TYPE 2 DIABETES  
Abstract 
 High levels of serum saturated fatty acids (SFAs) interfere with cellular functions 
and have been associated with type 2 diabetes. Dietary SFAs can promote inflammation 
and secretion of IgG autoantibodies and the pro-inflammatory cytokine IL-1β. This 
chapter explores the presence of anti-palmitic acid (PA) IgG autoantibodies in patients 
with type 2 diabetes and correlates these antibodies with diabetes health parameters. We 
retrospectively analyzed serum samples from several cohorts of patients with and without 
type 2 diabetes, some of whom participated in a health education intervention that 
resulted in improved diabetes management. Anti-PA IgG was identified in several 
patients in all cohorts. Specifically, all patients in one cohort with unmanaged diabetes 
tested positive for anti-PA IgG and showed a significant reduction in anti-PA IgG 
following a 3 month educational intervention. Serum anti-PA autoantibodies 
demonstrated high avidity, were specific for long-chain SFAs, and correlated with serum 
FAs in patients with managed type 2 diabetes. Interestingly, we found that anti-PA IgG 
neutralized PA-induced IL-1β secretion from dendritic cells. Taken together, our data 
shows that non-esterified SFAs can be recognized by IgG autoantibodies from human 
sera. Identification of anti-PA IgG autoantibodies in human serum opens avenues of 
research for identification of lipid induced immune responses.  
  
. 
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Introduction 
Growing evidence in the literature supports the role of increased dietary intake of 
saturated fats in the initiation of inflammation (Munoz and Costa 2013, Santos, Oliveira 
et al. 2013). Although elevated plasma levels of non-esterified FAs have been extensively 
correlated to insulin resistance, the role of specific FAs, such as palmitic acid (PA), is not 
well understood (Cascio, Schiera et al. 2012, Martins, Nachbar et al. 2012). Obesity is 
closely associated with increased levels of pro-inflammatory cytokines (Esser, Legrand-
Poels et al. 2014). Visceral adipose tissue is a major site of obesity-induced 
inflammation, and dyslipidemia is a major factor in the recruitment of activated immune 
cells such as macrophages, T cells, NK cells, dendritic cells, and B cells to visceral 
adipose tissue. Infiltrating adipose immune cells are a major source of pro-inflammatory 
cytokines in obesity-induced inflammation and type 2 diabetes (Oliver, McGillicuddy et 
al. 2010, Wong, Kyle et al. 2011, Esser, Legrand-Poels et al. 2014). In particular, the pro-
inflammatory cytokine IL-1β can directly cause insulin resistance in insulin-sensitive 
cells (Ehses, Lacraz et al. 2009, Dinarello, Donath et al. 2010, Kawai and Akira 2010, 
Grishman, White et al. 2012, Esser, Legrand-Poels et al. 2014). Moreover, PA has been 
shown to activate Toll-like receptor 4 on immune cells and induce secretion of IL-1β 
(Luo, Yang et al. 2012).  
Recently, B cells have been recognized as a major contributor to obesity-induced 
inflammation (Olefsky and Glass 2010, Winer and Winer 2012, Esser, Legrand-Poels et 
al. 2014, Sam and Mazzone 2014). B cells are recruited to adipose tissue in response to a 
high fat diet (Duffaut, Galitzky et al. 2009, Winer, Winer et al. 2014). The importance of 
IgG antibodies secreted by B cells has been established in a mouse model of type 2 
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diabetes. For example, depletion of B cells results in protection against diabetes in mice 
fed a high fat diet (Winer, Winer et al. 2011). In addition, the transfer of IgG antibodies 
from obesity-induced diabetic mice to non-diabetic mice rapidly induces insulin 
resistance and glucose intolerance (Winer, Winer et al. 2011). These findings suggest that 
B cell secretion of autoantibodies may be critical regulators of insulin resistance. Parallel 
to mice studies, humans with type 2 diabetes have disease-associated changes in B cell 
function, but the role of these changes in disease pathogenesis is not well established. 
Insulin resistance in obese individuals is linked to autoantibodies directed against 
intracellular protein antigens such as Golgi snap receptor complex 1 and Bruton’s 
tyrosine kinase (Winer, Winer et al. 2011). There is the possibility that autoantibodies to 
lipids are generated in response to a high fat diet because the authors of that study only 
screened for protein antigens. For instance, autoantibodies to cholesterol have been 
detected in human serum (Horvath and Biro 2003). Moreover, IgM antibodies against 
FAs have been reported in multiple sclerosis as well as in human immunodeficiency virus 
(HIV) patients (Amara, Chaugier et al. 1994, Amara, Chaugier et al. 1994, Boullerne, 
Petry et al. 1996).  
The purpose of the present study was to investigate whether humans produce class 
switched IgG autoantibodies that recognize saturated FAs such as PA. To answer this 
question, we retrospectively analyzed serum from 2 different cohorts of obese 
individuals, including patients with and without type 2 diabetes and patients who 
participated in the diabetes intervention program, En Balance (Wheeler, Montgomery et 
al. 2012). Our results show that autoantibodies to PA are indeed detectable in human 
serum. 
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Materials and Methods 
Research Design and Methods 
This study consisted of analysis of serum samples from the BioServe 
biorepository in addition to serum samples from a 3-month diabetes education 
intervention (En Balance) designed to promote improved type 2 diabetes management in 
Hispanic adults (Metghalchi, Rivera et al. 2008, Ojo, Beeson et al. 2010, Peterson, 
Beeson et al. 2010, Salto, Cordero-MacIntyre et al. 2011). We measured IL-1β and 
antibodies to palmitic acid in these samples and correlated the values obtained from the 
En Balance samples with the original primary outcomes of that study. These outcomes 
included fasting blood glucose, hemoglobin A1c, and body composition. A total of 73 
Hispanic males and females with type 2 diabetes met the En Balance participation criteria 
as previously described (Ojo, Beeson et al. 2010, Salto, Cordero-MacIntyre et al. 2011).  
 
Ethics and Informed Consent (En Balance Study) 
The Loma Linda University Institutional Review Board (IRB) approved the En 
Balance study protocol and all participants gave written informed consent to participate. 
Signed consent forms for the study are stored in locked filing cabinets and cannot be 
linked to participant data according to Loma Linda University IRB protocol. 
 
Evaluative Measures (En Balance Study) 
Glucose, A1C, and insulin  
Two blood samples (12-14 hr fasting) were drawn from the participants at both 
baseline and 3 months and analyzed for glucose, A1C, and insulin. Additional samples 
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were stored frozen at -80°C for future analysis. 
Anthropometric measures and body fat composition 
Anthropometric measures (height, weight, waist circumference, hip 
circumference, and waist/hip ratio) were assessed at baseline and 3 months as previously 
described (Metghalchi, Rivera et al. 2008, Chukwueke, Firek et al. 2012). Body 
composition was assessed at baseline and at 3 months using a TANITA scale (Detecto, 
Web City, Missouri), bioelectric impedance technology, and a fan beam dual X-ray 
absorptiometry (DXA) Hologic Discovery A software version 12.6 (Waltham, MA) as 
previously described (Ojo, Beeson et al. 2010, Salto, Cordero-MacIntyre et al. 2011).  
 
Serum Samples for Detection of anti-PA IgG and IL-1β 
Serum samples from 46 En Balance participants were available for anti-PA 
antibody and IL-1β testing.  The baseline characteristics of these participants are 
presented in Table 3 with the exception of missing participant data. Twenty-one of these 
participants had paired serum samples from baseline and 3 months available for 
longitudinal analysis. Twelve participants had serum samples from only baseline and 13 
participants had serum samples from only 3 months. 
Serum samples (four groups with 20 serum samples each: Hispanic control, 
Hispanics with type 2 diabetes, Caucasian control, and Caucasians with type 2 diabetes) 
purchased from the BioServe biorepository (Beltsville, MD) were also tested for anti-PA 
antibody and IL-1β.  The samples were gender, age, and BMI matched against the 21 En 
Balance participants with paired samples. Exclusion criteria consisted of history of renal 
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disease, self-declared diabetic complications, tobacco use, and other medical histories 
including cancer history. 
 
Table 3. Study Participant Characteristics at Baseline (n valid and missing cases 
= 46; n valid cases = 37, n missing cases = 9) 
 Males (n = 8) Females (n =  33 )  
Age (years)   
         25-39  - - - 4 
         40-59  5 22 
         60+  3 7 
    Mean ±SD  56.25 ± 8.94 53.94 ± 10.17 
Weight (kg)   
         50-75 1 16 
         76-99 6 8 
         100+ 1 3 
    Mean ±SD 88.98 ± 16.28 75.79 ± 18.55 
Height (cm)   
         145-159 - - - 22 
         160-169 4 5 
         170+ 4 - - - 
    Mean ±SD**** 168.43 ± 4.60 153.83 ± 5.78 
BMI (kg/m2)   
         20-29 3 13 
         30-39 4 10 
         40+ 1 4 
Mean ±SD 31.41 ± 6.43 31.61 ± 7.11 
**** = p < 0.0001 
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Synthesis of Palmitoylated Bovine Serum Albumin 
Palmitoylation of BSA was performed by modifying a protocol developed by the 
Geffard laboratory (Amara, Chaugier et al. 1994, Amara, Chaugier et al. 1994, Boullerne, 
Petry et al. 1996). For this reaction, 10 mg of PA was dissolved in 10 mL of anhydrous 
methanol (Sigma-Aldrich) containing 100 μl of triethylamine (Sigma-Aldrich). To 
activate the carboxylic acid group, 200 mL of anhydrous dimethylformamide (DMF) 
solution containing ethylchloroformate (ETOCOCl) (Sigma-Aldrich) diluted 1/16 was 
added. The solution was incubated for 3 min at 4°C. Next, 200 mg FA-free BSA (Gemini 
Bio-Products) was dissolved in 10 mL of 1 mM CaCl2 1M phosphate buffer (pH 6.8) 
containing 100 μl of triethylamine (Sigma-Aldrich). The BSA solution was added to the 
PA solution and stirred for 1 hr at room temperature. The conjugates were purified by 
dialysis against 150 mL  of dimethylformamide, methanol, and 1 mM CaCl2 phosphate 
buffer (pH 6.8), vol/vol/vol overnight at room temperature (RT),  then against 1 mM 
CaCl2 1M phosphate buffer (pH 6.8) for 24 hours at RT. The mixture was dialyzed 
against PBS (pH 7.2) until precipitated phosphate became soluble, and filtered to remove 
any remaining precipitate. BSA-PA concentration was determined by measuring the 
optical density (OD) at 280 nm. 
 
ELISA 
An ELISA was developed for determining PA specific IgG autoantibodies in 
human serum using the Ready-Set-Go ELISA IgG kit (eBioscience) according to 
manufacturer protocol with the following exceptions. Plates were coated with 100 μL of 
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50 μg/mL PA-BSA or BSA. Serum samples were diluted 1:100 before use in ELISA. All 
samples were analyzed in triplicate.  
Antibody avidity was determined by a competition ELISA as previously 
described (Boullerne, Petry et al. 1996). Purified IgG at 2 μg/mL in PBS was pre-
incubated for 16 hrs at 4°C with BSA-PA at concentrations varying between 10-4 and 10-
11 M. After centrifugation at 10,000 x g for 30 min, 100 μL of the supernatants was 
analyzed by ELISA as described above. The avidity was defined as the concentration of 
BSA-PA required for 50% inhibition (IC50) of antibody binding to immobilized BSA-PA.  
 
Isolation of anti-PA IgG antibodies 
 Total IgG from 7 participant sera was isolated and purifed on PierceTM Protein G 
Chromatography Cartridges (Thermo Scientific) according to the manufacturer’s 
protocol. IgG that recognized BSA-PA was purified using the SulfoLink® 
Immobilization Kit for Proteins (Thermo Scientific) according to manufacturer’s 
instructions. BSA-PA was immobilized to resin via covalent thioester bonds, and this 
resin was used to pack the chromatography column. The anti-PA antibodies were then 
purified by affinity chromatography. 
 
Determination of anti-PA IgG Specificity 
 A lipid dot blot method was established to determine the reactivity of a panel of 
non-esterified FAs (from Sigma-Aldrich) and esterified palmitic acid (glycerol 
tripalmitate from Sigma-Aldrich and N-palmitoyl phosphytidyl ethanolamine from Enzo 
Life Sciences) to purified anti-PA IgG. Two μL of 0.2 M FAs dissolved in 100% 
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chloroform + 0.1% HCl were spotted onto nitrocellulose. After allowing the samples to 
completely dry, the membrane was blocked in Odyssey blocking buffer for 2 hrs. The 
lipid blots were probed with purified anti-PA antibodies overnight at 4°C. After washing 
the blot with PBS, anti-Human IgG conjugated to alkaline phosphatase (Sigma) was used 
as the secondary Ab. 
 
Anti-PA IgG Neutralization Assay 
 Monocytes (CD14+) were isolated from human peripheral blood (Lifestream 
blood bank) and cultured in 96-well plates at a density of 200,000 per well in RPMI-1640 
supplemented with 10% FBS, 1,000 U penicillin and streptomycin, 50 ng/mL GM-CSF, 
and 10 ng/mL IL-4 for 6 days to differentiate them into dendritic cells (DCs). The DCs 
were treated with 150 uM PA in a 1:1 ratio with BSA for 24 hrs in the presence of IgG 
Ab containing anti-PA IgG. A mixture of total IgG isolated from 5 Hispanics with type 2 
diabetes with high anti-PA IgG levels or a mixture of total IgG isolated from 2 samples 
which tested negative for anti-PA IgG was used at a concentration of 1.4 mg/mL. 
Preadsorption of PA was performed at 37°C for 2 hrs. The culture supernatant (50 ul), 
was analyzed for IL-1β by cytometric bead array. 
 
Determination of Serum Non-esterifed Fatty Acid Concentration 
 Using the Free Fatty Assay Colorimetric Kit (Cell Biolabs, Inc.), the 
concentration of free fatty acid in the serum samples diluted 1:2 was determined in 
duplicate following the manufacturer’s recommendations. 
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Cytometric Bead Array 
En Balance serum samples and cell culture supernatants were analyzed with 
human IL-1β flex set as described by the manufacturer (BD Biosciences) on MACSQuant 
flow cytometer (Miltenyi Biotecc).  Data analysis was accomplished with FACP array v3 
software. 
 
Statistical Analysis 
 Statistical analyses were calculated using SPSS for Windows Version 22 (SPSS, 
Inc, Chicago, Illinois) with type I error set at α = 0.05. The data are presented as means ± 
SD. Univariate and bivariate analyses were reported at baseline and at 3 months. 
Spearman’s correlation coefficient was used to determine associations between body 
composition, glucose, and insulin levels with IL-1β and anti-PA antibodies. The 
Wilcoxon signed-rank test was used to identify baseline to 3-month paired differences. 
The Mann-Whitney test was used for nonparametric unpaired data analysis of changes in 
anti-PA autoantibody and FFA levels. GraphPad Prism 6 non-linear regression with 
outliers automatically excluded was used to determine IC50.  
 
Results 
Detection of anti-PA IgG autoantibodies by ELISA 
 Lipids are generally considered poor immunogens, and immunoassays targeting 
lipids like PA are rare. We detected anti-PA IgM (data not shown) and IgG antibodies in 
serum by using a specialized ELISA (Figure 26) (Amara, Chaugier et al. 1994).  
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Figure 26. IgG antibodies from patient serum react with palmitoylated BSA. (A) Diagram 
of BSA palmitoylation sites. Seven accessible hydroxyl groups that can be palmitoylated 
are present on serine, tyrosine, or threonine of BSA. (B) Coomasie stained gel and SDS-
PAGE western blot of palmitoylated BSA (BSA-PA). Palmitoylated BSA migrates faster 
on the gel than BSA (66kDa) due to an increased (-) charge contributed by SDS association 
with the palmitoyl group. Total IgG antibodies isolated from Hispanics with type 2 diabetes 
bind to BSA-PA but not to BSA (C) ELISA identification of anti-PA IgG. En Balance 
baseline serum samples from Hispanic diabetic patients were tested by ELISA for IgG Abs 
that react with BSA or BSA-PA. The cut-off value for positive antibody reactivity against 
BSA-PA (>0.186) was defined as an absorbance greater than two standard deviations above 
the mean value for BSA. Statistical analysis was accomplished with a Wilcoxon-ranked 
sign test. **** = p < 0.0001. 
 
 
Because adsorbent 96-well plates bind protein and not FAs, we conjugated the FA of 
interest, PA, to BSA in order to stably coat the plates with PA. The acylation reaction of 
BSA with PA occurs via an SN2 mechanism which results in O-palmitoylation of serine, 
tyrosine, and threonine in BSA (Figure 26A, B and Figure 27A and B). Due to the 
orientation of the palmitoyl groups on BSA, only the carbon chain is an accessible 
epitope for Ab binding (Figure 27B). We adopted this published approach with slight 
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modifications and demonstrated that class switched IgG antibodies which recognize PA 
can be identified in human serum (Figure 26C) (Boullerne, Petry et al. 1996). 
 
 
Figure 27. O-Palmitoylation of BSA. (A) The donated hydrogen from PA associates with 
Cl- to form HCl and two palmitate anions associate with Ca2+ to form calcium palmitate. 
The negatively charged palmitate allows a nucleophilic attack on ethylchloroformate 
(EtOCOCl). The Cl- is removed as a leaving group and an activated palmitate (anhydride) 
is formed. DMF = Dimethylformamide. (B) Available hydroxyl groups on BSA perform a 
nucleophilic attack on the activated palmitate via an SN2 mechanism. The leaving group 
is removed and the BSA is O-palmitoylated. 
 
 
Anti-PA IgG Autoantibody Specificity for Long Chain Saturated FAs 
To further characterize the antibodies which recognize BSA-PA, we isolated the 
total IgG fraction and anti-PA IgG autoantibodies from 5 En Balance participants with 
the highest antibody levels to determine Ab specificity and avidity. Using a novel lipid 
dot blot method constructed in our laboratory and a panel of fatty acids (Table 4), we 
found that anti-PA IgG can recognize non-esterified palmitic acid (16:0).  
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Table 4. Panel of Fatty acids tested against anti-PA IgG. 
Fatty Acid 
Degree of 
Saturation 
Carbon  
Chain Length 
Double bond position 
Butyric Acid saturated 6 N/A 
Palmitic Acid saturated 16 N/A 
Stearic Acid saturated 18 N/A 
Lignoceric Acid saturated 24 N/A 
Palmitoleic Acid monounsaturated 16:1 cis-∆9 
Oleic Acid monounsaturated 18:1 cis-∆9 
Elaidic Acid monounsaturated 19:1 trans-∆9 
Linoleic Acid polyunsaturated 18:2 cis,cis-Δ9,Δ12 
Arachidonic polyunsaturated 20:4 
cis,cis,cis,cis-
Δ5Δ8,Δ11,Δ14 
Docosahexaenoic 
Acid 
polyunsaturated 22:6 
cis,cis,cis,cis,cis,cis-
Δ4,Δ7,Δ10,Δ13,Δ16,Δ19 
 
 
In addition, we found the PA autoantibodies cross react with stearic acid (18:0), 
lignoceric acid (24:0), and elaidic acid (19:1) (Figure 28A).We also determined that the 
anti-PA IgG recognizes palmitic acid esterified to glycerol but not to phosphate (Figure 
28B). Both total IgG fractions and the purified anti-PA IgG reacted with the same fatty 
acids. Next, we modified this dot blot approach to determine whether the anti-PA 
antibodies could bind to non-esterified PA in the presence of physiological 
concentrations of BSA. Figure 28C indicates that a PA dot blot probed with total IgG 
fraction containing anti-PA IgG still binds to PA in the presence of 750μM BSA. In 
addition, we determined the avidity of the anti-PA IgG autoantibodies for BSA-PA. 
Following the protocol published by Boullerne et al. (Boullerne, Petry et al. 1996), we 
used a competition ELISA to determine that the avidity of anti-PA IgG to BSA-PA was 
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approximately 2.07x10-9 (Figure 28D). 
 
 
Figure 28. Specificity of anti-PA IgG autoantibodies for long chain saturated FAs. (A) 
Lipid dot blot of a panel of non-esterified FAs. The indicated FAs were probed with 
purified IgG or purified anti-PA IgG as the primary antibody. Anti-human IgG conjugated 
to alkaline phosphatase was the secondary Ab. The blots represent Abs isolated from the 
sera of 5 En Balance participants positive for anti-PA IgG. (B) Lipid dot blot comparison 
of non-esterified and esterified palmitic acid. The indicated molecules were probed with 
purified IgG or purified anti-PA IgG as the primary Ab. Anti-human IgG conjugated to 
alkaline phosphatase was the secondary Ab. The blots are representative of 3 experiments. 
(C) Dot blot binding assay. The ability of anti-PA to bind to palmitic acid in the presence 
of physiological levels of BSA (750uM) was tested. (D) Competition ELISA determination 
of anti-PA IgG avidity. Log C is the log10 of the concentration of the competitor BSA-PA 
in mol/L. The ratio between the absorbances with competition (B) and without competition 
(B0) is plotted. Each data point represents the mean ratio of absorbances ± SEM of 
antibodies from 5 participant sera. 
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Anti-PA IgG Autoantibodies Are Detectable in Both Diabetic and Non-diabetic 
Cohorts 
After validation of the ELISA technique to identify anti-PA autoantibodies, we set 
out to determine if these antibodies play a role in type 2 diabetes. We tested for the 
presence of PA autoantibodies in the sera of 46 Hispanics with type 2 diabetes and 
assessed the impact of their participation in the En Balance program on antibody levels. 
Out of a total of 67 serum samples, paired samples (baseline vs. 3 month intervention) 
were available for only 21 participants. The remaining 26 participants had only a baseline 
or three month serum sample. We found that 100%  (36/36) of the Hispanics with type 2 
diabetes tested positive for anti-PA IgG autoantibodies before undergoing the diabetes 
education program (Figure 29A).  
Interestingly, the frequency of participants in the En Balance program which 
tested positive for anti-PA autoantibodies was significantly decreased to 49% (20/41) 
after 3 months (Figure 29A).More importantly, the relative levels of anti-PA 
autoantibodies in individual participants (N = 21) from baseline (mean ± SEM = 1.05 ± 
0.121) to 3 months (mean ± SEM = 0.25 ± 0.030) were significantly reduced (Figure 
29B). This reduction in anti-PA autoantibodies coincided with improved diabetes control 
as described in previous publications (Table 5) (Metghalchi, Rivera et al. 2008, Ojo, 
Beeson et al. 2010, Salto, Cordero-MacIntyre et al. 2011, Chukwueke, Firek et al. 2012, 
Wheeler, Montgomery et al. 2012).  
To determine whether these results are cohort, disease, or ethnicity specific, we 
tested serum samples from the BioServe biorespository. We found that approximately 
30% of Caucasian control samples (7/21) and 33% of samples from Caucasians with type  
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Figure 29. Detection of anti-PA autoantibodies in human serum. (A) Anti-PA IgG in serum 
of Hispanic En Balance participants with type 2 diabetes is reduced following 3 months of 
diabetes education. Each data point represents the mean optical density of anti-PA IgG 
antibodies detectable by ELISA. The cut-off value for positive antibody reactivity against 
BSA-PA (>0.186) was defined as an absorbance greater than two standard deviations above 
the mean value for BSA. The frequency of sera positive for each group is indicated as a 
percent on the graph. (B) Paired data from the 21 En Balance participants with both 
baseline (mean ± SEM = 1.05 ± 0.121) and 3 month serum (mean ± SEM = 0.25 ± 0.030) 
samples. The black lines connect data points belonging to the same participant. Data was 
analyzed by Mann-Whitney (for A) and Wilcoxon test (for B). (C) Frequency of anti-PA 
IgG Abs in serum samples from Bioserve biorepository. CC= Caucasian control; CD= 
Caucasian diabetic; HC = Hispanic control; HD= Hispanic diabetic. The cut-off value for 
positive antibody reactivity against BSA-PA (>0.166) was defined as an absorbance greater 
than two standard deviations above the mean value for BSA. (D) Comparison of anti-PA 
IgG levels among En Balance serum samples and Bioserve biorepository serum samples. 
The median of all corrected OD values (OD450 of BSA-PA reactivity – OD450 of BSA 
reactivity) for each sample was determined. The corrected OD value for each sample was 
divided by the median to obtain the Multiple of the Median (MoM). A MoM value of 1 is 
considered the “normal” range for the anti-PA autoantibody. BL= En Balance baseline 
samples; 3 Mo= En Balance 3 month samples. Data was analyzed by Mann-Whitney. **** 
= p < 0.0001. 
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2 diabetes (6/20) tested positive for anti-PA IgG by ELISA (Figure 29C). Overall, 
samples from Hispanic cohorts showed an increased frequency of patients who tested 
positive for anti-PA IgG. Serum from Hispanic controls were 55% positive (11/20) while 
serum from Hispanics with type 2 diabetes were 50% positive (10/20). The frequencies of 
serum samples positive for anti-PA IgG in the Hispanic cohorts from the BioServe 
biorepository (55% and 50%) are similar to that of serum samples from the En Balance 
(49%) cohort after 3 months of intervention. 
Lastly, to compare anti-PA autoantibody levels across all groups, we performed 
multiple of the median (MoM) analysis. This type of analysis normalizes data with “1” 
corresponding to “normal” levels and also measures how far an individual test result 
deviates from the median. MoM is commonly used to report the results of medical 
screening test that tend to be highly variable (Bishop, Dunstan et al. 1993). First, we 
corrected the anti-PA IgG optical density values at OD450 by subtracting out the OD450 
values obtained by reacting each serum sample with BSA alone. We then found the 
median of the all the corrected OD450 values from both the Bioserve and the En Balance 
samples. Each sample’s OD450 value was divided by this median to obtain the MoM 
value. We found that only the baseline serum samples from the En Balance study 
significantly deviated from “normal” values in this data set (Figure 29C). This may 
indicate that high anti-PA antibody titers are related to how well type 2 diabetes is 
managed. 
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Table 5. Study Participant Clinical Characteristics with complete datasets at Baseline and 
3 months, n = 13. Values are presented as the Mean ± SD. 
Variables Baseline 3 Months Mean Difference p-value 
Anti-Palmitic Acid IgG  
(corrected ODa)  
0.79 ± 0.40 0.17 ± 0.09 0.71 ± 0.44 0.001 
IL-1β (pg/mL)  1.09 ± 0.46 0.98 ± 0.38 0.100 ± 0.44 0.442 
Fasting Glucose 
(mg/dL) 
153.77 ± 65.12 143.62 ± 61.95 10.15 ± 19.36 0.050 
HbA1c (%) 7.70 ± 2.16   6.76 ± 1.36   0.94 ± 1.18   0.005 
HbA1c (mmol/mol) 61.00 ± 23.60  50.00 ± 14.90   11.00 ± 12.90  0.005 
Insulin (pmol/L)  90.48 ± 74.88 99.30 ± 115.68 -8.88 ± 64.74 1.00 
Cholesterol (mg/dL)  170.23 ± 33.51 158.54 ± 38.40 11.69 ± 31.60 0.184 
HDL Cholesterol 
(mg/dL) 
45.00 ± 8.19 48.00 ± 7.916 -3.00 ± 4.43 0.049 
LDL Cholesterol 
(mg/dL) 
98.62 ± 25.92 93.15 ± 25.35 5.46 ± 21.89 0.382 
Cholesterol/HDL ratio 
(%)  
3.86 ±0.85 3.35 ± 0.67 0.50 ± 0.63 0.023 
Triglycerides (mg/dL)  249.38 ± 174.09 191.92 ± 36.15 57.46 ± 98.02 0.075 
TANITAb Fat Mass 
(kg)  
36.15 ± 12.40 33.98 ± 11.63 2.16 ± 2.45 0.013 
TANITAb Fat Percent 
(%)  
42.25 ± 7.27 40.56 ± 7.43 1.66 ± 1.97 0.034 
Scale Weight (kg)  83.74 ± 16.10 82.17 ± 15.38 1.56 ± 3.20 0.100 
Waist Circumference 
(cm)  
101.43 ± 9.73 99.89 ± 10.33 1.54 ± 5.36 0.196 
Hip Circumference 
(cm)  
111.05 ± 13.91 111.94 ± 12.76 -0.89 ± 3.82 0.294 
BMI (kg/m2)  32.33 ± 6.33 32.11 ± 5.54 0.22 ± 2.64 0.039 
DXAc-Trunk Fat (kg)  16.60 ± 43.79 15.66 ± 41.20 0.94 ± 1.06 0.007 
DXAc-Trunk Percent 
Fat (%) 
37.55 ± 6.78 36.36 ± 6.49 1.18 ± 1.68 0.041 
DXAc-Total Fat (kg) 31.81 ± 11.06 30.27 ± 10.21 1.53 ± 1.86 0.013 
DXAc-Total Percent 
Fat (%) 
36.94 ± 8.11 35.90 ± 7.85 1.04 ± 1.18 0.012 
aOptical Density 
bA brand of bioelectric impedance technology which measures body composition. TANITA 
scales  
  measure within 5% of DXA  
cDXA-Dual-energy X-ray absorptiometry 
109 
Anti-PA Autoantibodies Neutralize PA-induced Secretion of Dendritic Cell IL-1β 
To further understand what functions anti-PA autoantibodies have in the body, we 
determined anti-PA effects on PA-induced secretion of IL-1β from dendritic cells in the 
presence of BSA (Figure 30A). We found that pre-absorption of PA with IgG antibodies 
from patients with high levels of anti-PA but not from patients who tested negative for 
anti-PA IgG, significantly reduced secretion of IL-1β (Figure 30A). This result suggests 
that anti-PA IgG sequester non-esterified FAs in the blood. In support of this hypothesis, 
we found that anti-PA antibodies negatively correlate with serum IL-1β in the En 
Balance cohort at baseline (spearman r= -0.34, p=0.026 ) and at 3 months ( spearman r=-
0.26, p= 0.05). 
 
 
Figure 30. Anti-PA IgG neutralizes PA induced IL-β secretion from DCs in the presence 
of BSA. (A) Dendritic cells were cultured with 150μM PA (in 1:1 ratio with BSA) in the 
presence of a mixture of IgG antibody isolated from 5 En Balance participants who tested 
positive for anti-PA IgG (black bars) or in the presence of a mixture of IgG antibody 
isolated from 2 En Balance participants who tested negative for the antibody after the 3 
month intervention (white bars). PA+Ab(pre) indicates dendritic cells that were treated 
with PA preadsorbed for 2 hrs with total IgG from the two groups described. After 24 hrs, 
media from the cell cultures was analyzed by cytometric bead array for IL-1β. Data was 
analyzed by One-Way Anova. * = p < 0.05. (B) Illustration of the potential mechanism for 
the generation of anti-PA IgG. 
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Anti-PA Autoantibodies and Serum IL-1β from Hispanic Participants with Type 2 
Diabetes Correlates with Diabetes Health Variables 
In addition to measuring PA autoantibodies, we determined the concentration of 
IL-1β present in the serum of En Balance participants. We found that serum IL-1β levels 
did not change from baseline to 3 months (Table 5). Next, we performed multivariate 
analysis of anti-PA autoantibodies, IL-1β, and the health variables collected from each 
participant at baseline and at 3 months. Surprisingly, we found that anti-PA 
autoantibodies negatively correlated with body fat (Table 6). In addition, the levels of IL-
1β correlated to HbA1c values (Table 6).  
 
Table 6. Anti-PA autoantibodies and IL-1β from serum of Hispanics with type 2 diabetes 
correlate with body composition and HbA1c respectively. 
Variables N 
Spearman 
Correlation 
p-value 
Correlated with Anti-PA IgG    
     DXAa- Total Fat (kg)  27 -0.429 0.025 
     DXAa-Trunk Percent Fat 
(%)  
27 -0.404 0.003 
Correlated with IL-1β    
     HbA1c (%)  27 0.383 0.048 
aDXA-Dual-energy X-ray absorptiometry 
 
 
Total Non-esterified Fatty Acids Correlate with Anti-PA IgG Levels. 
Finally, we measured the concentration of total non-esterified fatty acid (both 
bound and free) in all serum samples. As expected, total FA in serum was significantly 
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higher in the diabetic cohorts as compared to the non-diabetic controls (Figure 31B). In 
the ethnic and T2D combined group, the levels of serum FA did not correlate with the 
levels of anti-PA IgG detected in the serum samples (Figure 31A). Because no significant 
correlations of anti-PA autoantibodies with improved diabetes control (Table 5) or serum 
FA were found, we analyzed the data according to the published American Diabetes 
Association target ranges for fasting blood glucose (FBG). We found that the levels of 
FFA correlate with anti-PA IgG levels (n= 24, Spearman’s rho 0.4862, p = 0.16) for 
individuals whose FBG was in the target range of 70-130 mg/dL. However, the levels of 
FFA do not correlate with anti-PA IgG levels for individuals whose diabetes is 
unmanaged (FBG > 130 mg/dL). 
 
 
 
Figure 31. Serum non-esterified serum FA. (A) XY plot of anti-PA IgG and non-esterified 
serum FA for all serum samples in this study. (B) Bar graph of serum non-esterified FA 
among diabetic and non-diabetic cohorts. CC= Caucasian control; CD= Caucasian 
diabetic; HC = Hispanic control; HD= Hispanic diabetic. Data was analyzed by Mann-
Whitney. * = p < 0.05, * = p < 0.01. 
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Discussion 
In this chapter, IgG autoantibodies against PA were shown to be detectable in 
human serum (Figures 26 and 28). IgG antibodies are principally active during a 
secondary antibody response driven by T cells. Therefore, the emergence of anti-PA IgG 
autoantibodies coincides with maturation of an antibody response, which occurs upon 
repeated exposure to an antigen. We also demonstrated that conjugation to the carrier 
protein BSA is not necessary for anti-PA IgG to recognize PA (Figures 28A and 29). The 
anti-PA antibodies we found can recognize non-esterified palmitic acid as well as 
palmitic acid esterified to glycerol (Figure 29B), indicating that these antibodies could 
potentially function both in the blood and in the tissue where saturated fatty acids are 
stored as triglycerides. 
Characterization of anti-PA IgG autoantibodies revealed that they are not specific 
for PA, but rather bind to long chain saturated FAs (Figure 28 and Table 4). Anti-PA IgG 
did not recognize butyric acid (6:0), indicating that these antibodies do not recognize 
short chain saturated FAs. Interestingly, we found that anti-PA did not recognize oleic 
acid (18:1) but did recognize elaidic acid (19:1). Both oleic and elaidic acid are 
monounsaturated long chain FAs, but only elaidic acid is recognized. We speculate that 
this result is due to the double bond being in the trans- rather than cis- configuration 
(Table 4), therefore structurally mimicking a saturated FA (Figure 27A). Further, we did 
not detect any IgG antibodies which bind to polyunsaturated FAs, supporting the notion 
that polyunsaturated FAs are anti-inflammatory (30).  
Of particular significance is that our data clearly show that anti-PA autoantibodies 
were reduced in serum samples obtained from Hispanics with type 2 diabetes after 3 
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months of culturally sensitive diabetes education (Figure 29). In this same cohort of 
participants, blood glucose, hemoglobin A1c, body fat, and dietary fat were also 
significantly reduced, indicating that managing diabetes through diet and exercise can 
result in a reduction of PA autoantibodies (Table 4 and (23, 25-28)). However, we could 
not correlate any one parameter to the levels of anti-PA IgG or to the change in antibody 
levels. We speculate that a mechanism indirectly related to serum FA or dietary intake of 
saturated fat may underlie the generation of the anti-PA antibody.  
Our data also showed that anti-PA IgG are found both in the diabetic and non-
diabetic condition. Interestingly, Hispanic participants presented with the anti-PA 
antibody about 20% more frequently than Caucasian subjects (Figure 29C). Another 
point to note is that the amount of antibody in the Caucasian cohort did not differ 
between diabetic and non-diabetic. On the other hand, the serum from BioServe Hispanic 
controls had statistically significant higher levels of anti-PA IgG than the serum from 
BioServe Hispanic diabetes samples (Figure 29C). The only group that had serum levels 
of anti-PA IgG above control or “normal” levels were from the En Balance participants at 
baseline (Figure 29D). These participants not only had type 2 diabetes, but at baseline, 
their diabetes was unmanaged (Table 4). Further characterization of the relationship 
between diabetes management and anti-PA IgG, antibody levels could potentially lead to 
using anti-PA antibody as an additional biological indicator in the management of type 2 
diabetes. 
Table 6 demonstrates that anti-PA autoantibodies negatively correlate with body 
fat and that IL-1β positively correlates with HbA1c. These correlations seem 
counterintuitive because increased adiposity is associated with low-grade chronic 
114 
inflammation. However, obesity and increased BMI were shown to be associated with 
impaired antibody responses (Sheridan, Paich et al. 2012, Paich, Sheridan et al. 2013, 
Young, Gray et al. 2013). Our study shows that increased fat is associated with reduced 
production of anti-PA autoantibodies, a result which corroborates the literature 
observations (Sheridan, Paich et al. 2012, Paich, Sheridan et al. 2013, Young, Gray et al. 
2013). The correlation of serum IL-1β with HbA1c supports current convention that IL-
1β is strongly associated with insulin resistance and type 2 diabetes (Lagathu, Yvan-
Charvet et al. 2006, Esser, Legrand-Poels et al. 2014).   
We found that IgG from Hispanics with type 2 diabetes neutralized the secretion 
of IL-1β from DCs (Figure 30A). Previous studies have determined that IgG 
autoantibodies generated in type 2 diabetes are pathogenic (Winer, Winer et al. 2011, 
Winer, Winer et al. 2014). An alternative possibility requiring further exploration is that 
anti-PA IgG are generated as a protective mechanism against increased plasma non-
esterified saturated FAs and subsequent inflammation and insulin resistance (Figure 
30B). In “managed” diabetes, total serum non-esterified FAs correlate with the levels of 
anti-PA IgG. However, they do not correlate in “unmanaged” diabetes, indicating 
possible dysregulation of what may be a normal process of antibody production. Further 
research is necessary to determine what mechanisms link saturated fatty acids to the 
production of anti-PA IgG. Based on the available data, our current hypothesis is that 
increased non-esterified PA resulting from excess calories (or overeating) and obesity 
stimulates the production of anti-PA autoantibodies through an indirect mechanism such 
as palmitoylating serum proteins (Figure 30B). Because we observed class switched IgG 
autoantibodies (Figure 26, 28, and 29) we speculate that generation of anti-PA 
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autoantibodies is antigen and T cell dependent (MacLennan, Gulbranson-Judge et al. 
1997). These autoantibodies may then sequester non-esterified SFAs and may help 
mitigate SFA induced inflammatory responses. The natural function of anti-PA IgG in 
the body remains unknown. If the role of anti-PA IgG in the healthy state and in 
unmanaged type 2 diabetes can be further validated, a new avenue in understanding and 
treatment of these conditions is possible. Potentially, these antibodies could be used as a 
therapeutic if they are found to be protective. Alternatively, they could be used as 
indicators of diabetes management. Understanding how poor type 2 diabetes management 
impacts anti-PA IgG production and lipid immunology could have an important impact 
on the future of type 2 diabetes research.  
The main objective of the present study was to determine whether there are 
detectable levels of anti-PA autoantibodies in normal or diabetic patients and our findings 
support the existence of such autoantibodies. Future studies need to further explore the 
significance of this finding using larger cohorts of normal, pre-diabetic and diabetic 
patients. We propose that our findings raise the need to investigate the role of lipid 
autoantibodies in healthy conditions and in type 2 diabetes to further our understanding 
of lipid immunology. 
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CHAPTER SIX 
CONCLUSIONS AND FUTURE DIRECTIONS 
Summary 
This body of research explored the relationships between palmitic acid and human 
immune cells and their possible implications in type 2 diabetes. Chapter 1 summarizes 
the role that fatty acids and immune cells play in the development of type 2 diabetes.  
From this review, it is clear that the recruitment of monocytes to visceral adipose tissue 
and subsequent differentiation into dendritic cells may play an important role in obesity-
induced inflammation (Figure 31). Chapter 2 describes the necessity of histone H1 down-
regulation and proper histone acetylation during monocyte differentiation into dendritic 
cells. Understanding epigenetic regulation of DC differentiation is the first step to 
defining what governs this process in the presence of palmitic acid, a likely scenario 
during diabetes inflammation. In chapter 3 and 4, the mechanism by which PA activates 
TLR4 on DCs and induces secretion of pro-inflammatory cytokines is discussed (Figure 
31). Lastly, chapter 5 introduces a clinical aspect. Patients with unmanaged type 2 
diabetes have high levels of antibodies that recognize PA. The precise role of these newly 
identified antibodies is unclear. Whether they are pathogenic or beneficial, it has become 
increasingly clear that they have a large implication for both diabetes research and lipid 
immunology. 
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Figure 32. Summary. Diets high in palmitic acid lead to hypertrophic adipose tissue, 
increased lipolysis, and increased serum palmitic acid. Monocytes differentiate into DCs 
which can be affected by elevated concentrations of palmitic acid. PA activates DCs and 
induces secretion of IL-1β. Pro-inflammatory IL-1β is attributed to induction of insulin 
resistance and the onset of type 2 diabetes. In unmanaged type 2 diabetes, the production 
of anti-PA IgG antibodies are observed.  
 
 
 
Future Directions 
Aims 
Saturated FAs, e.g. palmitic acid (PA), are pro-inflammatory and have been 
associated with metabolic syndrome, insulin resistance, and various immunological 
complications (Kim, Pham et al. 2007, Riserus 2008, Titov, Krylin et al. 2011). In 
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diabetes patients, serum saturated FAs are correlated with inflammation (Riserus 2008, 
Unger and Parkin 2010, Virtanen, Niinisto et al. 2010). Our laboratory has shown that the 
impact of PA on the immune system in type 2 diabetes can be partially attributed to their 
interaction with DCs and possibly B cells. While our laboratory has shown the pro-
inflammatory effects of PA on DC function, complete elucidation of the molecular 
mechanisms by which PA impact DCs requires further investigation. 
 Our long-term goal is to understand how high fat diets may drive obesity-induced 
inflammation in order to identify targets for the development of new diabetes 
therapeutics. The overall objective of future research is to define the molecular 
mechanisms underlying palmitic acid induction of inflammation. Our central hypothesis 
is that monocytes differentiate into mature (activated) DCs in the presence of PA, and 
that these activated DCs can mount not only an innate but also an adaptive immune 
response. This hypothesis is based on data from this dissertation and current literature 
showing that (1) PA binds TLR4 on DCs and induces secretion of pro-inflammatory 
cytokines associated with chronic inflammation in adipocytes; (2) Obesity-induced 
inflammation increases the numbers of pro-inflammatory T cells in the visceral adipose 
tissue (Nishimura, Manabe et al. 2009), and PA-treated DCs seem to activate CD8+ T 
cells (Figure 33). (3) Lastly, antibodies that recognize PA are present at high levels in 
patients with unmanaged type 2 diabetes (Figure 29). The rationale behind the proposed 
research is that understanding mechanisms of PA induced inflammation will aid the 
design of pharmacological agents which target inflammatory pathways responsible for 
obesity-induced inflammation and subsequent type 2 diabetes. Therefore, we will test our 
central hypothesis according to the following aims:  
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Aim 1: Characterize PA Modulation of DC Differentiation from Monocytes 
Working Hypothesis:  In the presence of PA, monocytes differentiate into mature, 
activated DCs. We will use mass spectrometry and Ingenuity Pathway Analysis to 
determine changes in the DC proteome as well as monitor post-translational 
modifications that occur in response to differentiation in the presence of PA.   
 
Aim 2: Determine the Mechanism of PA Induced T Cell Activation 
Working hypothesis: PA activated DCs may produce a pro-inflammatory 
response in T cells. To test this hypothesis, we will determine T cell phenotypic and 
cytokine profiles by flow cytometry after DC/T cell co-cultures in the presence of PA. 
Furthermore, we will use neutralizing antibodies against CD1 to determine if PA 
mediated T cell activation is CD1 dependent. 
 
Aim 3: Determine the Role of Anti-PA Antibodies in Type 2 Diabetes 
Our working hypothesis is that anti-PA antibodies are natural protective 
antibodies that reduce the level of free PA in the body. To determine whether anti-PA 
antibodies are protective or pathogenic, we will analyze and correlate the levels of anti-
PA IgG, pro-inflammatory cytokines, palmitoylated proteins, and serum lipids before and 
after a lipid challenge in healthy and diabetic subjects. We will also use mass 
spectrometry and immunoprecipitation with anti-PA antibodies to determine all antigens 
recognized by the antibody.  
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Experimental Approach 
Aim 1: Characterize PA Modulation of DC Differentiation from Monocytes 
In vivo, the differentiation of dendritic cells from monocytes occurs in a 
microenvironment. In type 2 diabetes, this microenvironment is likely to be high in 
saturated free fatty acids. Therefore, it is important to understand how DC differentiation 
in a microenvironment with high concentrations of PA may affect downstream function. 
It is known that DCs differentiated in the presence of PA are hyper responsive to LPS 
stimulation (Zeyda, Saemann et al. 2005, Wang, Hao et al. 2007, Kong, Yen et al. 2010). 
Therefore, we hypothesize that, in the presence of PA, monocytes differentiate into 
mature, activated DCs.  
To test this hypothesis we will differentiate monocytes using either GM-CSF + 
IL-4 or with GM-CSF + IL-4 + PA. Once differentiated, we will isolate the protein from 
the cells and label them with TMT-reagents for quantification by mass spectrometry. The 
changes in the DC proteome will be assessed and specific attention will be given to 
histone changes and post translational modifications we previously determined to be 
important in DC differentiation (Chapter 2, Figures 8 and 9). Ingenuity Pathway Analysis 
will be used to assess if PA differentiated DCs have a pro-inflammatory phenotype. 
Lastly, in vitro assays will be used to assess the effects of PA on DC differentiation. 
Levels of costimulatory factors, MHC molecules, CD1 molecules, and secreted cytokines 
will be analyzed.  
 
Aim 2: Determine the Mechanism of PA Induced T Cell Activation 
Preliminary data show that human peripheral blood treated with PA have 
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increased numbers of CD8+CD127+ T cells and that CD5+ on CD8+ T cell proliferation is 
increased (Figure 33). In addition, PA treated DCs have a pro-inflammatory phenotype 
manifested by increased surface CD86 and secretion of IL-1β, IFN-α, and IL-23 that 
would support the differentiation of pro-inflammatory T cells (Figures 15 and 20). 
Because this pro-inflammatory cytokine profile could support Th17 and CTL 
development, we will use PA modulated DC-T cell co-cultures to assess whether PA 
treated DCs can stimulate the differentiation of pro-inflammatory T cells. Using flow 
cytometry and cytometric bead array, we will measure markers of Th17 and CTLs to 
determine their relative abundance and activation in response to PA treated DCs after 5 
days of co-culture.  
Upon determining whether PA treated DCs can stimulate pro-inflammatory T cell 
development, we will assess the role of CD1b, an MHC-like molecule, in this interaction. 
Because antigen presentation and stimulation of the T cell receptor is a requirement for T 
cell activation, we believe that excess PA is presented on DCs as a CD1b bound lipid 
antigen. Proteins and lipoproteins are presented on MHCI and MHCII, but this is not 
possible for lipids. Lipids are presented exclusively on a family of MHC-like proteins 
called CD1 molecules (Schiefner and Wilson 2009). Our preliminary data showed that 
PA may associate with CD1b on DCs (Figure 25C). 
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Figure 33. Effects of PA on CD8+ T cells in Human Peripheral Blood. Peripheral blood 
was treated with 300uM PA complexed 2:1 with BSA for 5 days. Samples were stained 
and analyzed by flow cytometry. (A) The percent of total lymphocytes CD3, CD8, and 
CD127 positive. (B) The Mean fluorescent intensity (MFI) of CD5 on CD3+CD8+ cells 
(CTLs). 
 
 
 
Initially, the special relationship of the PA analog (BODIPY C-16) to CD1b will 
be confirmed by confocal microscopy. To determine the cellular location of the CD1b 
molecules, we will perform Z-stack analysis in addition to comparing surface staining 
with intracellular staining. In a second set of experiments, we will assess whether PA-
induced DC stimulation of T cells is dependent on CD1 presentation of PA. During 5 day 
DC-T cell cultures in the presence of PA, a neutralizing Ab against CD1b will be used 
assess the role of CD1b in DC mediated T cell activation.  The T cells will be harvested 
and prepared for analysis by flow cytometry as mentioned in the above paragraph. 
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Aim 3: Determine the Role of Anti-PA Antibodies in Type 2 Diabetes 
Our preliminary data indicates that anti-PA antibodies may be protective due to 
their ability to inhibit secretion of IL-1β from DCs exposed to PA in vitro (Figure 30). To 
determine whether these antibodies have a beneficial function in vivo, a prospective 
clinical study will be designed in which palmitate turnover will be measured in patients 
with and without type 2 diabetes after a bolus injection of 13C-labeled palmitate as 
described in previous studies (Jensen, Haymond et al. 1989). Palmitate turnover will then 
be correlated with measured levels of anti-PA antibodies as well as assessment of clinical 
parameters to determine whether anti-PA antibodies play a role in enhancing PA 
metabolism. Additionally, we will isolate these antibodies (see Chapter 5) and use them 
for immunoprecipitation of serum antigens followed by mass spectrometry to identify 
other possible antigens or immunogens responsible for generating the antibody response. 
   
Conclusions 
The body of work presented here, in addition to the proposed future research, will 
begin to fill the void in the field of lipid immunology. Understanding lipid immunology 
will shed light on mechanisms by which diet derived saturated fatty acids induce 
inflammation. This dissertation has produced two key findings that have great potential to 
assist our understanding of the pathophysiology of type 2 diabetes and the approach taken 
to treat the disease.  
The first major finding is that palmitic acid is a ligand for TLR4. This ligand –
receptor interaction provides a direct link for the reported association between increased 
serum fatty acids in type 2 diabetes and inflammation and insulin resistance (See Chapter 
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1). Over-consumption of saturated fats leads to obesity which results in high levels of 
lipolysis and increased serum saturated free fatty acid levels. Palmitic acid, the most 
abundant of these saturated fatty acids can interact directly with cells expressing TLR4. 
These include but are not limited to DCs, macrophages, and B cells. If this type of innate 
immune activation is an early event in type 2 diabetes development, then targeting PA 
induced TLR4 signaling would be a promising prospect. The knowledge of how strongly 
PA binds TLR4 can aid in the design of small molecule inhibitors that would interfere 
with this interaction but preserve binding of natural ligands such as LPS. Therefore, 
immune responses to invading pathogens could be preserved.  
The second key finding produced by this dissertation is the existence of antibodies 
that recognize PA in patients with unmanaged type 2 diabetes. This finding implies that a 
high fat diet can either directly, or indirectly induce an adaptive immune response, a 
concept supported in the literature (Lee and Lee 2014). Although the role these FA 
antibodies play in type 2 diabetes is currently unknown, their potential use in the field of 
diabetes is immense. To begin with, if anti-PA antibodies are highly produced when 
diabetes is unmanaged, they can serve as a good biomarker for physicians to assess 
disease management. Second, if anti-PA antibodies are protective and aid in the clearance 
of serum saturated fatty acids, it could potentially be used as a therapeutic. A monoclonal 
Ab against saturated fatty acids with an Fc portion that facilitates degradation by 
macrophages could be an approach to regulate serum lipids and subsequent chronic 
inflammatory signaling. Alternatively, anti-PA antibodies may be pathogenic, enhance 
inflammation through FcR signaling, or form antibody complexes that promote diabetic 
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nephropathy. Defining a pathogenic role for this antibody could provide an additional 
target for treatment of diabetes inflammation and its complications.  
Overall, this dissertation has enhanced the knowledge of mechanisms underlying 
fatty acid mediated inflammation. The basic concept that a simple fatty acid can be a 
potent dietary immune modulator sets the stage for expansion of lipid immunology and 
general application of this knowledge to various systemic disease conditions such as 
lupus erythematosus, arthritis, spinal cord injury, and type 2 diabetes. 
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